4-1BB targeting agents for the treatment of cancer

WO2026239384A1PCT designated stage Publication Date: 2026-11-19YEDA RES & DEV CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2026/050398
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current cancer treatments using CD137 agonist antibodies face low efficacy and high toxicity, including adverse events such as hepatitis, due to systemic overstimulation of T-cells, necessitating a safer and more targeted therapeutic approach.

Method used

Development of a mutated 4-1BB ligand polypeptide with specific mutations that reduce signaling by at least 100-fold and no more than 10,000-fold, combined with an antibody targeting intratumor T cells, and optionally a PD-1 blocking antibody, to enhance anti-tumor activity while minimizing liver toxicity.

Benefits of technology

The mutated 4-1BB ligand polypeptide and PD-1 blocking antibody combination significantly enhances anti-tumor activity with reduced liver toxicity, demonstrating improved therapeutic efficacy in animal models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IL2026050398_19112026_PF_FP_ABST
    Figure IL2026050398_19112026_PF_FP_ABST
Patent Text Reader

Abstract

An isolated polypeptide is disclosed. The polypeptide comprises at least one monomer of a 4- IBB ligand (4-1BBL) having at least one mutation which reduces 4- IBB signaling, when comprised in a homotrimer, by at least 100 fold and no more than 10,000 fold, as compared to a wild-type homotrimer of 4-1BBL, wherein the polypeptide has an anti-tumor activity, wherein the polypeptide binds specifically to 4- IBB.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 4-1BB TARGETING AGENTS FOR THE TREATMENT OF CANCER

[0002] RELATED APPLICATIONS

[0003] This application claims the benefit of priority of U. S. Patent Application No. 63 / 803,994 filed May 12, 2025, the contents of which are incorporated herein by reference in their entirety.

[0004] SEQUENCE LISTING STATEMENT

[0005] The XML file, entitled 107340.xml, created on May 10, 2026, comprising 101,677 bytes, submitted concurrently with the filing of this application is incorporated herein by reference.

[0006] FIELD AND BACKGROUND OF THE INVENTION

[0007] The present invention, in some embodiments thereof, relates to proteins that target 4- IBB for treating cancer.

[0008] The tumor necrosis factor receptor superfamily (TNFRSF) is a protein superfamily of receptors characterized by their ability to bind tumor necrosis factors (TNFs) via cysteine-rich pseudorepeats in the extracellular domain. At present, 27 TNF family members have been identified. TNFRSF members and their ligands are expressed mostly on immune cells, where they are playing a role of immunomodulators in T-cell-mediated immune responses. TNFRSF members play a role in enhancement of dendric cell survival and priming capacity of T cells, optimal generation of effector T cells, optimal antibody responses, and amplification of inflammatory reactions.

[0009] CD 137 (4-1BB, TNF-receptor superfamily 9, TNFRSF9) is a surface glycoprotein of the TNFR superfamily. It is an inducible costimulatory T cell receptor. CD 137 expression is activation¬ dependent, and encompasses a broad subset of immune cells including activated NK and NKT cells, regulatory T cells, dendritic cells (DC) including follicular DC, stimulated mast cells, differentiating myeloid cells, monocytes, neutrophils, eosinophils, and activated B cells. In addition, CD 137 expression has also been demonstrated on tumor vasculature.

[0010] CD137-Ligand (CD137L, 4-1 BBL or tnfsfP), a molecule of the TNF family, is an intercellular natural ligand known for CD 137. The ligand for CD 137 forms a homotrimer, and the signaling via CD 137 proceeds from ligated molecules at the cell surface, which become cross¬ linked by trimerized ligand. The higher order clustering of CD 137 was thus suggested to be necessary for mediating the signaling. CD 137 associates with the adaptors TRAF-2 and TRAF-1 in its cytoplasmic tail, resulting in coimmunoprecipitation, which is enhanced upon CD137 activation in T cells. Recruitment of TRAF-1 and TRAF-2 by CD 137 results in downstream

[0011] activation of NFKB and the Mitogen Activated Protein (MAP) Kinase cascade including ERK, JNK, and p38 MAP kinases. NFkB activation leads to upregulation of Bfl-1 and Bcl-XL, prosurvival members of the Bcl-2 family. The pro-apoptotic protein Bim is downregulated in a TRAF-1 and ERK dependent manner.

[0012] CD137 co-stimulates T cells to carry out effector functions such as eradication of established tumors, broadening primary CD8+T cell responses, and enhancing the memory pool of antigen-specific CD8+T cells, induction of interferon-gamma (IFN-γ) synthesis. The critical role of CD137 stimulation in CD8+ T-cell function and survival could be potentially utilized for the treatment of tumors through manipulation of the CD 137 / CD 137L function. In fact, in vivo efficacy studies in mice have demonstrated that treatment with anti-CD137 antibodies led to tumor regressions in multiple tumor models.

[0013] Two anti-CD137 antibodies currently in the clinic are urelumab (Bristol-Myers Squibb), a fully humanized IgG4 mAb, and utomilumab (PF-05082566, Pfizer), a fully human IgG2 mAh. Although utilization of therapeutic antibodies agonizing CD 137 is a very promising treatment strategy, it is coupled with such difficulties as low efficacy of anti-CD137 agonist antibodies, high toxicides and adverse events.

[0014] CD 137 agonist antibodies were shown to lead to alterations in immune system and organ function increasing risks of toxicides. Initial clinical studies into the human therapeutic use of CD137 agonist antibody have also demonstrated elevations of liver enzymes and increased incidence of hepatitis. Potentially fatal hepatitis was observed in a Bristol-Myers Squibb (BMS) phase II anti-CD137 study for previously treated stage IHZIV melanoma, National Clinical Trial (NCT) 00612664. This study and several others (NCT00803374, NCT00309023, NCT00461110, NCT00351325) were terminated due to adverse events (Chester C., et al.. Cancer Immunol Immunother Oct; 65(10): 1243-8 (2016)). Such adverse events are most probably due to systemic overstimulation of T-cells.

[0015] To gain additional cross-linking function and achieve certain levels of TNRSF, in particular CD137, activation, it has been recently suggested to use multivalent and multispecific fusion polypeptides that bind PDL-1 and TNRSF members, or folate receptor alpha (FRa) and TNRSF members, wherein the binding to PDL-1 or FRa is capable of providing additional crosslinking function (WO 2017 / 123650).

[0016] PDL-1 (CD274, B7-H1) is a 40 kDa type I transmembrane protein. PDL-1 is a surface glycoprotein ligand for PD-1, a key immune checkpoint receptor expressed by activated T and B cells and mediates immunosuppression. PDL-1 is implicated in the suppression of immune system responses during chronic infections, pregnancy, tissue allografts, autoimmune diseases, and cancer.

[0017] PDL-1 downregulates T cell activation and cytokine secretion by binding to PD-1. PD-1, activated by PDL-1, potentially provides an immune-tolerant environment for tumor development and growth. PDL-1 also negatively regulates T-cell function through interaction with another receptor, B7.1 (B7-l, CD80).

[0018] Inhibition of the PDL-l / PD-1 interaction allows for potent anti-tumor activity. A number of antibodies that disrupt the PD-1 signaling have entered clinical development. These antibodies belong to the following two main categories: those that target PD-1 (nivolumab, Bristol-Myers Squibb; pembrolizumab, Merck, Whitehouse Station, NJ; pidilizumab, CureTech, Yavne, Israel) and those that target PDL-1 (MPDL3280A, Genentech, South San Francisco, CA; MED14736, MedImmune / AstraZeneca; BMS-936559, Bristol-Myers Squibb; MSB0010718C, EMD Serono, Rockland, MA).

[0019] The combination of anti-PDL-1 and anti-CD137 antibodies increased overall survival and enhanced T-cell effector function in the ID- 8 ovarian adenocarcinoma model (Duraiswamy J, et al., Cancer Res 73:6900-6912 (2013)). The combination of urelumab (anti-CD137) with nivolumab (anti- PD -1) in both solid tumors and B -cell non-Hodgkin's lymphoma is being tested in a phase I / II trial (NCT02253992), while PF-05082566 (anti-CD137) is being tested in a phase lb trial with pembrolizumab (anti- PD-1) in patients with solid tumors (NCT02179918) (Chester C., et al., Cancer Immunol Immunother Oct; 65(10): 1243-8 (2016)).

[0020] Recently, the effect of multivalent and multispecific fusion polypeptides that bind PDL-1 and CD 137 has been evaluated in vitro on T-cell activation and proliferation. Using an autologous in vitro co-culture system implementing immature DC and donor matched T-cells, it has been demonstrated that INBRX-105, a multispecific and multivalent polypeptide having two PDL-1 binding domains, two CD137 binding domains and an Fc region, is superior in stimulating interferon- gamma production, when compared to the monospecific PDL-1 sd-Ab-Fc fusion protein, the CD 137 sdAb-Fc fusion protein, the combination of the two, the anti-PDL-1 antibody atezolizumab, the anti-CD137 antibody utomilumab (PF-05082566), or the anti-PDL-1 antibody prembrolizumab, and combinations thereof, at inducing INTy or mediating CD8+T-cell proliferation and activation (WO 2017 / 123650). Additionally, WO 2016 / 149201 discloses certain antibodies directed against PDL-1 and suggests creating bi specific antibody constructs further comprising a T-cell engaging antibody, with CD 137 being contained in a non-exclusive list of more than 20 potential T-cell targets.

[0021] In spite of numerous treatment options for patients suffering from cancer, there remains a need for effective and safe therapeutic agents and a need for their preferential use in a more targeted manner. Immune-modulating biologies offer promising approaches in treatment of cancers due totheir modes of actions, however global immunostimulation and lack of any restriction of this immunomodulation to pathologically relevant cells and sites causes numerous side effects and significant toxicides, which potentially may lead to increased morbidity and mortality of patients. It is therefore an object of the present invention to provide a medicament to improve treatment of a proliferative disease, particularly a cancer.

[0022] Background art includes US Patent No. 12202911B2.

[0023] SUMMARY OF THE INVENTION

[0024] According to an aspect of the present invention there is provided an isolated polypeptide comprising at least one monomer of a 4- IBB ligand (4-1BBL) having at least one mutation which reduces 4- IBB signaling, when comprised in a homotrimer, by at least 100 fold and no more than 10,000 fold, as compared to a wild-type homotrimer of 4-1BBL, wherein the polypeptide has an anti-tumor activity, wherein the polypeptide binds specifically to 4- IBB.

[0025] According to an embodiment of the present invention, the at least one mutation reduces induction of NFKB.

[0026] According to an embodiment of the present invention, the polypeptide is a single-chain homotrimer.

[0027] According to an embodiment of the present invention, the at least one monomer has a mutation at position 100, 115 and / or 152, wherein coordinates of the position are according to SEQ ID NO: 1.

[0028] According to an embodiment of the present invention, the at least one monomer comprises at least one of the following mutations: V152L, V100K, V152K, L115D or V100H.

[0029] According to an embodiment of the present invention, the at least one monomer comprises a V152L mutation.

[0030] According to an embodiment of the present invention, the at least one monomer comprises an amino acid sequence at least 90 % identical to SEQ ID NO: 2.

[0031] According to an embodiment of the present invention, the at least one monomer comprises the amino acid sequence as set forth in SEQ ID NOs: 5-8.

[0032] According to an embodiment of the present invention, the at least one monomer comprises three monomers and comprises the amino acid sequence as set forth in SEQ ID NOs: 21-24.

[0033] According to an embodiment of the present invention, the polypeptide is attached to an antibody having an Fc region, wherein the antibody targets a protein on intratumor T cells.

[0034] According to an embodiment of the present invention, the protein is an immune checkpoint protein.

[0035] According to an embodiment of the present invention, the polypeptide is covalently attached to the antibody.

[0036] According to an embodiment of the present invention, the polypeptide is covalently attached to the antibody via a linker.

[0037] According to an embodiment of the present invention, the linker comprises an amino acid sequence as set forth in SEQ ID NO: 4.

[0038] According to an embodiment of the present invention, the polypeptide is attached to the Fc region.

[0039] According to an embodiment of the present invention, the Fc region comprises a mutation which reduces binding to an Fc receptor.

[0040] According to an embodiment of the present invention, the Fc region is Fc receptor silent.

[0041] According to an embodiment of the present invention, the mutation is a EAEA mutation.

[0042] According to an embodiment of the present invention, the immune checkpoint protein is selected from the group consisting of PD-1, PDCTLA-4, TIGIT, LAG-3, TIM-3, ICOS, BTLA, 4-1BB, GITR and OX-40.

[0043] According to an embodiment of the present invention, the immune checkpoint protein is PD-1.

[0044] According to an embodiment of the present invention, the antibody is a PD-1 blocking antibody.

[0045] According to an embodiment of the present invention, the antibody is a PD-1 non-blocking antibody.

[0046] According to an embodiment of the present invention, the polypeptide comprises complementary determining regions (CDRs) as set forth in SEQ ID NOs: 9-11 in a heavy chain with an N to C orientation and CDRs as set forth in SEQ ID NOs: 12-14 in a light chain with an N to C orientation.

[0047] According to an embodiment of the present invention, the polypeptide comprises CDRs as set forth in SEQ ID NOs: 15-17 in a heavy chain with an N to C orientation and CDRs as set forth in SEQ ID NOs: 18-20 in a light chain with an N to C orientation.

[0048] According to an aspect of the invention, there is provided an article of manufacture comprising the polypeptide of disclosed herein and a PD-1 blocking antibody and / or a PDL-1 antibody.

[0049] According to an aspect of the invention, there is provided method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the polypeptide disclosed herein, thereby treating the cancer.

[0050] According to an embodiment of the present invention, the polypeptide is for use in treating cancer.

[0051] According to an embodiment of the present invention, the article of manufacture is for use in treating cancer.

[0052] According to an embodiment of the present invention, the method further comprises administering to the subject a second agent simultaneously or sequentially with the polypeptide, wherein the second agent is a PD-1 blocking antibody and / or a PDL-1 antibody.

[0053] According to an embodiment of the present invention, the cancer is selected from the group consisting of: bladder cancer, breast cancer, uterine / cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, kidney cancer, head and neck cancer, lung cancer, stomach cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, neoplasm of the central nervous system, lymphoma, leukemia, myeloma, sarcoma, and virus-related cancer.

[0054] According to another aspect of the invention, there is provided a pharmaceutical composition comprising the polypeptide described herein.

[0055] According to an embodiment of the present invention, the pharmaceutical composition further comprises a PD-1 blocking antibody and / or a PDL-1 antibody.

[0056] According to another aspect, there is provided a nucleic acid encoding the polypeptide described herein.

[0057] According to another aspect, there is provided a expression vector comprising the nucleic acid described herein.

[0058] According to another aspect, there is provided a cell transformed with the expression vector described herein.

[0059] According to another aspect, there is provided a method of producing a polypeptide comprising:

[0060] (a) culturing the cell of claim 35 under conditions which allow the expression of the polypeptide; and

[0061] (b) isolating the polypeptide from the cell.

[0062] According to another aspect, there is provided a 4- IBB agonistic antibody which binds specifically to 4- IBB and comprises CDRs of Urelumab, wherein at least one of the CDRs comprises at least one amino acid substitution which reduces 4- IBB signaling by at least 50 fold and no more than 10,000 fold, wherein the molecule has an anti-tumor activity.

[0063] According to embodiments described herein, the at least one mutation is in a heavy chain of the antibody.

[0064] According to embodiments described herein, the at least one mutation is selected from the group consisting of W34A, G100A, Y104G and W106Y, wherein the numbering is according to the wild type sequence as set forth in SEQ ID NO: 51.

[0065] According to embodiments described herein, the at least one mutation is in a light chain of the antibody.

[0066] According to embodiments described herein, the at least one mutation is selected from the group consisting of Y32A, Y32N, Q89G, N93G, W94G, P95G and L98G, wherein the numbering is according to the wild type sequence as set forth in SEQ ID NO: 52.

[0067] According to still another aspect of the invention, there is provided a bispecific antibody comprising:

[0068] (i) a first antigen binding moiety which specifically binds to 4- IBB and comprises CDRs of Urelumab, wherein at least one of the CDRs comprises at least one amino acid substitution which reduces 4- IBB signaling by at least 50 fold and no more than 10,000 fold; and

[0069] (ii) a second antigen binding moiety which specifically binds to a protein on intratumor T cells,

[0070] the bispecific antibody having anti-tumor activity.

[0071] According to embodiments described herein, the protein is an immune checkpoint protein.

[0072] According to embodiments described herein, the immune checkpoint protein is selected from the group consisting of PD-1, PDCTLA-4, TIGIT, LAG-3, TIM-3, ICOS, BTLA, 4-1BB, GITR and OX-40.

[0073] According to embodiments described herein, the immune checkpoint protein is PD-1.

[0074] According to embodiments described herein, the antibody is a PD-1 blocking antibody.

[0075] According to embodiments described herein, the antibody is a PD-1 non-blocking antibody.

[0076] According to still another aspect, there is provided a pharmaceutical composition comprising the antibody described herein.

[0077] According to embodiments described herein, the pharmaceutical composition further comprises a PD-1 blocking antibody and / or a PDL-1 blocking antibody.

[0078] According to still another aspect, there is provided an article of manufacture comprising the antibody described herein and an additional PD-1-blocking antibody or PDL-1 blocking antibody.

[0079] According to still another aspect there is provided a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the bispecific antibody described herein, thereby treating the cancer.

[0080] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains.

[0081] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and / or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

[0082] BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[0083] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

[0084] In the drawings:

[0085] FIGs. 1A-D illustrate rational for the development of PD-1 targeted 4- IBB therapy

[0086] (A.) C57BL / 6 mice with established MC-38 tumor were treated with 4- IBB antibody (LOB 12.3 and 3H3 clones), PD-1 antibody (RMP1.14 clone), or combination treatments (4-1BB + PD-1). 200 ug Ab / injection. Mice where then followed for tumor progression n=7. (B) Tumor growth at day 24. (C). H& E staining livers following treatment (day 26) Scale 500 um. (D.) Liver Immune cell infiltration following PD-1 treatment (RMP1.14), 4-1BB (3H3 and LOB12.3) and combination treatment. Unless otherwise stated or in case of n < 3, results are presented as means ± SEM. Stars indicate a significant p value as calculated by the relevant statistical test.

[0087] FIGs. 2A-J illustrate a proof of concept of potency of 4-1BBL anti-tumor activity.

[0088] (A.) Design of 4-1BB ligand. (B.) C57BL / 6 h4-lBB mice with established MC-38 tumor were treated either with 1H3-LAGA-4-1BBL or Urelumab N297Q 200ug / dose every 3 days n=8 (C.) Tumor volume at day 17. (D.) ALT enzyme level measurement at day 7. (E.) Liver cell immune infiltration at day 20. (F.) Graphical abstract of RMP1.14-4-1BBL, (G.) B. C57BL / 6 h4-1BB mice with established MC-38 tumor were treated either with PD-1-4-BBL (RMP1.14 clone), 1H3-LAGA-4-1BBL lOOug / dose every 3 days. (H.) Tumor volume at day 17. (I). Survival curve. (J)ALT enzyme level measurement at day 7. Unless otherwise stated or in case of n < 3, results are presented as means ± SEM. Stars indicate a significant p value as calculated by the relevant statistical test.

[0089] FIGs. 3A-Q illustrate fine-tuning to find the optimal attenuation level for PD-1-4-1BBL.

[0090] (A.) From the left, Size exclusion chromatography (SEC) of RMP1-14-4-1BBL V100K, mPD-1 binding ELISA and h4-lBB cell-based reporter potency assay. (B.) C57BL / 6 h4-lBB micewith established MC-38 tumor were treated either with control PBS or RMP1-14-4-1BBL-V100K lOOug / dose every 3 days n=7 (C.) ALT enzyme level measurement at day 7. (D.) From the left, RMP1-14-4-1BBL V152K SEC, mPD-1 binding ELISA and h4-lBB cell-based reporter potency assay. (E) C57BL / 6 h4-lBB mice with established MC-38 tumor were treated either with control PBS or RMP1-14-4-1BBL-V125K lOOug / dose every 3 days n=9 (F.) ALT enzyme level measurement at day 7. (G.) From the left, Size exclusion chromatography (SEC) of RMP1-14-4-1BBL V152L, mPD-1 binding ELISA and h4-lBB cell-based reporter potency assay (H.) C57BL / 6 h4-lBB mice with established MC-38 tumor were treated either with control PBS or RMP1-14-4-1BBL-V125L lOOug / dose every 3 days n=7 (I.) ALT enzyme level measurement at day 7. (J.) From the left, RMP1-14-4-1BBL-115D-V100H SEC, mPD-1 binding ELISA and h4-lBB cellbased reporter potency assay. (K.) C57BL / 6 h4-lBB mice with established MC-38 tumor were treated either with control PBS or RMP1-14-4-1BBL-115D-V100H lOOug / dose every 3 days n=10 (L.) ALT enzyme level measurement at day 7. (M.) From the left, RMP1-14-4-1BBL V100K LI 15D SEC, mPD-1 binding ELISA and h4-lBB cell-based reporter potency assay. (N.) C57BL / 6 h4-lBB mice with established MC-38 tumor were treated either with control PBS or RMP1-14-4-1BBL- V100K L115D lOOug / dose every 3 days n=7 (O.) ALT enzyme level measurement at day 7. (P.) Comparison of anti-tumor activity RMP1-14-4-1BBL-115D-V100H and RMP1-14-4-1BBL-V152L lOOug / dose every 3 days n=10. (Q.) h4-lBB mPD-1 h4-lBB cell-based reporter potency assay of RMP1-14-4-1BBL V152L.

[0091] FIGs. 4A-G illustrate anti-tumor activity and toxicity of selected RMP.14 / 4-1BBL V152L vs Urelumab.

[0092] (A) C57BL / 6 h4-lBB mice with established MC-38 tumor were treated either with control PBS, Urelumab N297Q or RMP1-14-4-1BBL-V152L lOOug / dose every 3 days n=7 (B.) ALT enzyme level measurement at day 7. (C.) Liver cell immune infiltration at day 20 (D.) Individual tumor volumes. (E.) C57BL / 6 h4-lBB mice with established MC-38 tumor were treated either with control PBS, RMP1-14-4-1BBL V152L or 1H3 / 4-1BBL V152L lOOug / dose every 3 days n=7 (F.) tumor volume at day 10. (G.) ALT enzyme level measurement at day 7.

[0093] FIGs. 5A-J illustrate that PD-1 blocking is required for PD-1-4-1BBL therapy.

[0094] (A) C57BL / 6 h4-lBB mice with established MC-38 tumor were treated either with control PBS or RMP1-14-4-1BBL-V152L 100ug / or 30ug / dose or RMP1-30-4-1BBL-V152L 100ug / or 30ug / dose every 3 days n=9 (B.) ALT enzyme level measurement at day 7. (C.) Survival proportions of treated mice described in Fig 5A. (D.) C57BL / 6 h4-lBB mice with established MC-38 tumor were treated either with control PBS, RMP1-14 N297A, RMP1-14-4-1BBL-V152L, RMP1-30-4-1BBL-V152L or RMP1-30-4-1BBL-V152L + RMP1-14 N297A with lOOug / dose

[0095] every 3 days n=9. (E.) ALT enzyme level measurement at day 7. (F.) Survival proportions of treated mice described in Fig 5D. (G.) MC-38 re-challenge (H.) Tumor volumes day 13. (I.) ALT enzyme level measurement at day 7. (J) From the left, Size exclusion chromatography (SEC) of RMP1-30-4-1BBL V152L, h4-lBB cell-based reporter potency assay mPD-1 binding ELISA.

[0096] FIGs. 6A-Q illustrate anti-tumor activity and toxicity of fully human PD-1-4-1BBL

[0097] (A) C57BL / 6 h4-lBB hPD-1 mice with established MC-38 tumor were treated either with control (Vehicle), Keytruda, Ureluman (N297Q), or Keytruda + Ureluman (N297Q) with lOOug / dose every 3 days n=10 (B.) ALT enzyme level measurement at day 7. (C.) Survival proportions of treated mice described in Figure 6A. (D.) C57BL / 6 h4-lBB hPD-1 mice with established MC-38 tumor were treated either with control (Vehicle), Keytruda, keytruda 4-1BBL WT, or Keytruda 4-1BBL-V152L with lOOug / dose every 3 days n=10 (E.) ALT enzyme level measurement at day 7. (F.) Survival proportions of treated mice described in Figure 6D. (G.) C57BL / 6 h4-lBB hPD-1 mice with established MC-38 tumor were treated either with control (Vehicle), 2H7 / 4-1BBL V152L either at 150 / 200 / 250 / 300 ug / dose every 3 days n=6 (H.) ALT enzyme level measurement at day 7. (I.) Survival proportions of treated mice described in Figure 6G. (J.) SEC of keytruda 4-1BBL V152L. (K.) Cell-based reporter potency assay of keytruda 4-1BBL WT vs keytruda 4-1BBL V152L. (L.) Direct ELISA of commercial keytruda and keytruda 4-1BBL V152L binding to human PD-1. (M.) Human PD-l / PDL-1 blocking cell-based reporter assay of commercial keytruda and keytruda 4-1BBL V152L. (N.) SEC of 2H7 / 4-1BBL V152L. (O.) Cell-based reporter potency assay of 2H7 / 4-1BBL WT vs 2H7 / 4-1BBL V152L. (P.) Direct ELISA of commercial 2H7 / 4-1BBL WT and 2H7 / 4-1BBL V152L binding to human PD-1. (Q.) Human PD-l / PDL-1 blocking cell-based reporter assay of 2H7 / 4-1BBL WT and 2H7 / 4-1BBL V152L.

[0098] FIGs. 7A-D illustrate anti-tumor activity and toxicity of combination treatment of hPD-1-4-lBBL+hPDL-l

[0099] (A). C57BL / 6 h4-lBB hPD-1 hPDL-1 mice with established B16F10 tumor were treated either with control (Vehicle), 2H7-4-1BBL V152L, Avelumab N297A, Urelumab (N297Q), 2H7-4-1BBL V152L + Avelumab N297A or Ureluman (N297Q) + Avelumab N297A with lOOug / dose for Avelumab and Urelumab and 200 ug / dose for 2H7-4-1BBL V152L, every 3 days n=9 (B.) ALT enzyme level measurement at day 7. (C.) Survival curve (D.) Individual mice tumor growth.

[0100] FIGs. 8A-D illustrate anti-tumor activity and toxicity of combination treatment of hPD-1-4-lBBL+hPDL-l

[0101] (A). C57BL / 6 h4-lBB hPD-1 hPDL-1 mice with established B16F10 tumor were treated either with control (Vehicle), 2H7-4-1BBL V152L, Atezolizumab N297A, Urelumab (N297Q),2H7-4-1BBL V152L + Atezolizumab N297A or Urelumab (N297Q) + Avelumab N297A with lOOug / dose for Atezolizumab, 60ug / dose for Urelumab and 200 ug / dose for 2H7-4-1BBL V152L, every 3 days n=10 (B.) ALT enzyme level measurement at day 7. (C.) Individual mice tumor growth. (D.) Individual survival curve.

[0102] FIG. 9 is a schematic representation of Bi-specific antibody agonist variant construction. The double headed arrows represent location of the CH / Cκ light chain arm exchange. IH3: Antihuman DNAse I clone 1H3 mAb; 2D7: Anti-human HLA Class I clone 2D7 mAb; bivalent Umabl: bivalent urelumab positive control; bi-specific nomenclature: Umab / IH3X where Umab, IH3 and X denote the agonist arm, the targeting arm and the position of the light chain arm exchange respectively.

[0103] FIGs. 10A-F are schematic representations of Bi-specific Urelumab PD1 antibodies.

[0104] DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

[0105] The present invention, in some embodiments thereof, relates to proteins that target 4- IBB for treating cancer.

[0106] Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

[0107] The present inventors initially showed that the combination of anti-PD- 1 therapy and anti-4- IBB therapy significantly improved anti-tumor activity compared to either 4- IBB monotherapy or PD-1 monotherapy alone (Figures 1A and B) without exacerbating the a4-lBB toxicity profile (Figure 1D).

[0108] Following the assessment of the beneficial combination of aPD-1 with a4-lBB treatment, the present inventors aimed to target 4- IBB agonism to PD-1+ cells combining these pathways for optimal antitumor activity while sparing liver toxicity.

[0109] One approach was to generate a PD-1-4-1BB ligand in which a PD-1 antibody was conjugated via a linker to 4-1BBL monomers (see for example Figure 2F). To address liver toxicity, the present inventors identified particular mutations which could potentially reduce 4- IBB ligand binding to its cognate receptor. Introduction of particular mutations were shown to attenuate the 4-1BBL arm. Surprisingly in-vivo anti-tumor activity of the molecule was preserved.

[0110] Whilst further reducing the present invention to practice, the present inventors determined that PD-1 blockage was required for optimal anti-tumor activity (Figures 5A-C). The present inventors showed that the PD-1 blockage can be carried out via the PD-1 arm of the PD-1-4-1BBligand, or alternatively by combining a non-blocking PD-1-4-1BB ligand with a blocking PD-1 antibody (Figures 7A-D and 8A-D).

[0111] Another approach was to generate a bispecific antibody targeting both PD-1 and 4- IBB, based on the known 4-1BB antibody Urelumab. Similarly to the PD-1-4-1BB ligand, in order to address liver toxicity, the present inventors introduced mutations to attenuate the 4-1BBL arm, which still preserved the anti-tumor activity.

[0112] Thus, according to a first aspect of the present invention, there is provided an isolated polypeptide comprising at least one monomer of a 4- IBB ligand (4-1BBL) having at least one mutation which reduces 4- IBB signaling, when comprised in a homotrimer, by at least 100 fold and no more than 10,000 fold, as compared to a wild-type homotrimer of 4-1BBL, wherein the polypeptide has an anti-tumor activity, wherein the polypeptide binds specifically to 4- IBB.

[0113] The term “4-1 BB” (also referred to herein as “CD137”) refers to a membrane glyocoprotein of the TNFR superfamily, in particular to human CD137 with UniProt ID number Q07011.

[0114] The term “4-1BB-L” (also referred to herein as “CD137-ligand”) refers to a molecule of the TNF family which serves as an intercellular natural ligand for 4- IBB, in particular to human 4-1BB-L. The natural ligand forms a homotrimer, wherein a single monomer of the trimer has a UniProt ID number P41273, reproduced herein as SEQ ID NO: 1. The 4-1BB extracellular domain of 4-1BB-L is set forth in SEQ ID NO: 2.

[0115] According to one embodiment, the polypeptide binds specifically to 4- IBB which is expressed on activated T cells. The phrase "specifically bind(s)" or "bind(s) specifically" when referring to a binding molecule refers to a binding molecule which has intermediate or high binding affinity, exclusively or predominately, to a target molecule, such as to 4- IBB. The phrase "specifically binds to" refers to a binding reaction which is determinative of the presence of a target protein (such as 4- IBB) in the presence of a heterogeneous population of proteins and other biologies. Thus, under designated assay conditions, the specified binding molecules bind preferentially to a particular target protein (e.g. 4- IBB) and do not bind in a significant amount to other components present in a test sample. Specific binding to a target protein under such conditions may require a binding molecule that is selected for its specificity for a particular target protein. A variety of assay formats may be used to select binding molecules that are specifically reactive with a particular target protein. For example, solid-phase ELISA immunoassays, immunoprecipitation, Biacore and Western blot may be used to identify binding molecules that specifically bind to 4- IBB. Typically, a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 times background. Given that the binding molecule is an antibody, the phrase "specifically binds to" refers to a binding reaction thatis determinative of the presence of the antigen (such as 4- IBB) in a heterogeneous population of proteins and other biologies. Typically, an agent that specifically binds to an antigen binds the antigen with a dissociation constant (KD) of at least about 1 x 10’6to IxlO-7, or about IxlO-8to IxlO-9M, or about IxlO10to IxlO11or higher; and / or binds to the predetermined antigen (e.g. 4-1BB) with an affinity that is at least two-fold, five-fold, ten-fold, twenty-fold greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.

[0116] The polypeptide of this aspect of the present invention comprises an amino acid sequence at least 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or 100 % identical (as determined using BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters) to the amino acid sequence of SEQ ID NO: 2, except that it comprises at least one mutation (e.g. a deletion, a substitution or an insertion).

[0117] The 4- IBB binding portion of the polypeptide may comprise a single copy of mutated SEQ ID NO: 2 (i.e. a single monomer), two copies of mutated SEQ ID NO: 2 (i.e. a single chain dimer) or 3 copies of mutated SEQ ID NO: 2 (i.e. a single chain trimer). In one embodiment, each monomer of the single chain dimer or trimer may be identical and have the same mutation (i.e. a single chain homodimer or homotrimer). In another embodiment, at least one monomer of the single chain dimer or trimer is non-identical (e.g. has a different mutation) to another monomer of the dimer / trimer. The two / three monomers of the single chain monomer / trimer may be directly fused (see for example SEQ ID NO: 3, 6, 7 and 8) or connected by a peptide linker.

[0118] Mutations contemplated by the present invention reduces 4- IBB signaling, as compared with the non-mutated 4-1BBL. Preferably, the mutated polypeptide (when generated as a homotrimer) reduce 4-1BB signaling by at least 100 fold, at least 200 fold, at least 500 fold, at least 1000 fold, at least 2000 fold, at least 3000 fold, at least 4000 fold or at least 5000 fold as compared to the wild-type non-mutated homotrimer (as set forth in SEQ ID NO: 3). In one embodiment, the mutated polypeptide (when generated as a homotrimer) reduce 4- IBB signaling by no more than 10,000 fold or no more than 5,000 fold as compared to the wild-type non-mutated homotrimer (as set forth in SEQ ID NO: 3). Reduction of 4- IBB signaling can be measured by analyzing the amount of a down-stream effector of 4- IBB activation, including for example intracellular NFKB, Bfl-1 and Bcl-XL. Thus, methods of measuring 4-1 BB signaling include use of a NFkB -Luciferase reporter gene assay, whereby a reduction of luciferase indicates a reduction of 4-1BB signaling. Such assays are manufactured by a number of companies e.g. Promega or BPS Biosciences.

[0119] Exemplary mutations contemplated by the present inventors include mutation (e.g. substitution) at position 100, 115 and / or 152, wherein coordinates of the position are according to SEQ ID NO: 1.

[0120] Contemplated substitutions include V152L, V100K, V152K, L115D and V100H. In particular the substitution may be a single V152L or the two substitutions (L115D and V100H).

[0121] Thus, the polypeptides of the present invention may comprise the amino acid sequence as set forth in SEQ ID NOs: 7 or 8.

[0122] According to a specific embodiment, the mutation is a V152L substitution and the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 7.

[0123] The 4- IBB binding portion of the polypeptides of the present invention may consist of the amino acid sequence as set forth in SEQ ID NOs: 21, 22, 23 or 24.

[0124] According to a specific embodiment, the mutation is a V152L substitution and the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 23.

[0125] As mentioned, the 4- IBB ligands of this aspect of the present invention have anti-tumor activity - e.g. capable of reducing tumor volume in animal models.

[0126] Assays which can be used to check anti-tumor activity are provided herein below:

[0127] Tumor formation in transgenic mice overexpressing an oncogene - A transgenic mouse model for cancer (e.g., breast cancer) such as the erb model (Shah N., et al., 1999, Cancer Lett.

[0128] 146: 15-2; Weistein EL, et al., 2000, Mol. Med. 6: 4-16) or MTV / myc model (Stewart TA et al., 1984, Cell, 38: 627-637), the c-myc model (Leder A., et al., 1986, Cell, 45:485-495), v-Ha-ras or c-neu model (Elson A and Leder P, 1995, J. Biol. Chem. 270: 26116-22) can be used to test the ability of the 4- IBB mutated ligands to suppress tumor growth in vivo.

[0129] Tumor formation in mice administered with cancerous cell lines - For the formation of solid tumors, athymic mice can be injected with human or animal (e.g., mouse) cancerous cells such as those derived from breast cancer, ovarian cancer, prosate cancer or thyroid cancer, and following the formation of cancerous tumors the mice can be subjected to intra-tumor and / or systemic administration of an agent capable of upregulating 4- IBB expression level and / or activity (e.g., by overexpression of 4-1BBL).

[0130] The following cell lines (provided with their ATCC Accession numbers) can be used for each type of cancer model:

[0131] For breast cancer:

[0132] Human breast cancer cell lines - MDA-MB-453 (ATCC No. HTB-131), MDA-MB-231 (ATCC No. HTB-26), BT474 (ATCC No. HTB-20), MCF-7 (ATCC No. HTB-22), MDA-MB-468, (for additional cell lines see pathdotcamdotacdotuk / ~pawefish / indexdothtml);

[0133] For ovarian cancer:

[0134] Human ovarian cancer cell lines - SKOV3 (ATCC No. HTB-77), OVCAR-3 HTB-161), OVCAR-4, OVCAR-5, OVCAR-8 and IGROV1;

[0135] For prostate cancer:

[0136] Human prostate cancer cell lines - DU-145 (ATCC No. HTB-81), PC-3 (ATCC No. CRL-1435);

[0137] For thyroid cancer:

[0138] Human derived thyroid cancer cell lines - FTC-133, KI, K2, NPA87, K5, WRO82-1, ARO89-1, DRO81-1;

[0139] For lung cancer:

[0140] Mouse lung carcinoma LL / 2 (LLC1) cells (Lewis lung carcinoma) - These cells are derived from a mouse bearing a tumor resulting from an implantation of primary Lewis lung carcinoma. The cells are tumorigenic in C57BL mice, express H-2b antigen and are widely used as a model for metastasis and for studying the mechanisms of cancer chemotherapeutic agents (Bertram JS, et al., 1980, Cancer Lett. 11: 63-73; Sharma S, et al. 1999, J. Immunol. 163: 5020-5028).

[0141] For melanoma:

[0142] Mouse B16-F10 cells (Melanoma) - The cells are derived from mouse (C57BL / 6J) bearing melanoma (Briles EB, et al., 1978, J. Natl. Cancer Inst. 60: 1217-1222).

[0143] Culturing conditions of cancerous cells - The cancerous cells can be cultured in a tissue culture medium such as the DMEM with 4 mM L-glutamine adjusted to contain 1.5 g / L sodium bicarbonate and 4.5 g / L glucose, supplemented with 10 % fetal calf serum (FCS), according to known procedures (e.g., as described in the ATCC protocols).

[0144] Tumor formation in animal models by administration of cancerous cells - Athymic nu / nu mice (e.g., female mice) can be purchased from the Jackson Laboratory (Bar Harbor, ME). Tumors can be formed by subcutaneous (s.c.) injection of cancerous cells (e.g., 2 x 106cells in 100 pl of PBS per mouse). Tumors are then allowed to grow in vivo for several days (e.g., 6-14 days) until they reach a detectable size of about 0.5 cm in diameter. It will be appreciated that injection of cancerous cells to an animal model can be at the organ from which the cell line is derived (e.g., mammary tissue for breast cancer, ovary for ovarian cancer) or can be injected at an irrelevant tissue such as the rear leg of the mouse.

[0145] In order to enhance anti-tumor potency, the present inventors contemplate targeting the mutated 4- IBB ligand to intratumor T cells. Accordingly, the present inventors contemplatelinking the mutated 4- IBB ligand to an antibody which is capable of specifically targeting intratumor T cells (e.g. can bind to an immune checkpoint protein on intratumor T cells).

[0146] As used herein, "immune checkpoint" refers to co-stimulatory and inhibitory signals that regulate the amplitude and quality of T-cell receptor recognition of an antigen. In certain embodiments, the immune checkpoint is an inhibitory signal. In some embodiments, the inhibitory signal is the interaction between Programmed Death- 1 (PD-1) and Programmed Death Ligand- 1 (PD-L1).

[0147] As used herein the term “immune checkpoint protein” refers to receptors or their cognate ligands present on the T cell surface that are capable of regulating an immune response to cancer cells. Examples of immune checkpoint proteins include, but are not limited to PD-1, CTLA-4, TIGIT, LAG-3, TIM-3, ICOS, BTLA, 4-1BB, GITR and OX-40.

[0148] According to a particular embodiment, the immune checkpoint protein is PD-1 (e.g., human PD-1). The " Programmed Death-1 (PD-1)" receptor refers to an immuno-inhibitory receptor belonging to the CD28 family. PD-1 is expressed predominantly on previously activated T cells in vivo, and binds to two ligands, PD-L1 and PD-L2. The term " PD-1" as used herein includes human PD-1 (hPD-1), variants, isoforms, and species homologs of hPD-1, and analogs having at least one common epitope with hPD-1. The complete hPD-1 sequence can be found under GenBank Accession No. AAC51773. In one embodiment, the PD-1 has the sequence as specified in GenBank Accession No. AAC51773.

[0149] It will be appreciated that antibodies to immune checkpoint proteins may bind human checkpoint proteins and / or mouse checkpoint proteins. Antibodies that bind both human and mouse are typically referred to as “pan-specific antibodies”.

[0150] Complementary determining sequences (CDRs), which can be used for generating PD-1 antibodies, according to some embodiments of the invention can be found in the antibodies listed herein below:

[0151] • Anti PD-1 CDR sequences from clone RMP1-14 are set forth in SEQ ID NOs: 9- 14 (blocking PD-1 antibody);

[0152] • Anti PD-1 sequences from clone RMP1-30 are set forth in SEQ ID NOs: 15-20 (non-blocking PD-1 antibody);

[0153] • Pembrolizumab (also named lambrolizumab or Keytruda (MK-3475 or SCH 900475), a humanized monoclonal IgG4 antibody against PD-1); (blocking PD-1 antibody). The terms Pembrolizumab and Keytruda are therefore used interchangeably;

[0154] • nivolumab (MDX 1106, BMS 936558, ONO 4538), a fully human IgG4 antibody that binds to and blocks the activation of PD-1 by its ligands PD-L1 and PD-L2; (blocking PD-1 antibody);

[0155] • Dostarlimab (Jemperli) is a humanized IgG4 antibody that binds to and blocks the activation of PD-1 by its ligands; (blocking PD-1 antibody)

[0156] The term "antibody" as used in this invention includes intact molecules as well as functional fragments thereof (that are capable of binding to an epitope of an antigen).

[0157] As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

[0158] According to a specific embodiment, the antibody fragments include, but are not limited to, single chain, Fab, Fab’ and F(ab')2 fragments, Fd, Fcab, Fv, dsFv, scFvs, diabodies, minibodies, nanobodies, Fab expression library or single domain molecules such as VH and VL that are capable of binding to an epitope of the antigen in an HEA restricted manner.

[0159] Suitable antibody fragments for practicing some embodiments of the invention include a complementarity-determining region (CDR) of an immunoglobulin light chain (referred to herein as “light chain”), a complementarity-determining region of an immunoglobulin heavy chain (referred to herein as “heavy chain”), a variable region of a light chain, a variable region of a heavy chain, a light chain, a heavy chain, an Fd fragment, and antibody fragments comprising essentially whole variable regions of both light and heavy chains such as an Fv, a single chain Fv Fv (scFv), a disulfide- stabilized Fv (dsFv), an Fab, an Fab’, and an F(ab’)2, or antibody fragments comprising the Fc region of an antibody.

[0160] As used herein, the terms "complementarity-determining region" or " CDR" are used interchangeably to refer to the antigen binding regions found within the variable region of the heavy and light chain polypeptides. Generally, antibodies comprise three CDRs in each of the VH (CDR HI or HI; CDR H2 or H2; and CDR H3 or H3) and three in each of the VL (CDR LI or LI; CDR L2 or L2; and CDR L3 or L3).

[0161] The identity of the amino acid residues in a particular antibody that make up a variable region or a CDR can be determined using methods well known in the art and include methods such as sequence variability as defined by Kabat et al. (See, e.g., Kabat et al., 1992, Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, NIH, Washington D. C.), location of the structural loop regions as defined by Chothia et al. (see, e.g., Chothia et al., Nature 342:877-883, 1989.), a compromise between Kabat and Chothia using Oxford Molecular's AbM antibody

[0162] modeling software (now Accelrys®, see, Martin et al., 1989, Proc. Natl Acad Sci USA. 86:9268; and world wide web site www(dot)bioinf-org(dot)uk / abs), available complex crystal structures as defined by the contact definition (see MacCallum et al., J. Mol. Biol. 262:732-745, 1996) and the "conformational definition" (see, e.g., Makabe et al., Journal of Biological Chemistry, 283:1156-1166, 2008).

[0163] As used herein, the “variable regions” and " CDRs" may refer to variable regions and CDRs defined by any approach known in the art, including combinations of approaches.

[0164] Functional antibody fragments comprising whole or essentially whole variable regions of both light and heavy chains are defined as follows:

[0165] (i) Fv, defined as a genetically engineered fragment consisting of the variable region of the light chain (VL) and the variable region of the heavy chain (VH) expressed as two chains;

[0166] (ii) single chain Fv (“scFv”), a genetically engineered single chain molecule including the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

[0167] (iii) disulfide-stabilized Fv (“dsFv”), a genetically engineered antibody including the variable region of the light chain and the variable region of the heavy chain, linked by a genetically engineered disulfide bond.

[0168] (iv) Fab, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme papain to yield the intact light chain and the Fd fragment of the heavy chain which consists of the variable and CHI domains thereof;

[0169] (v) Fab’, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin, followed by reduction (two Fab’ fragments are obtained per antibody molecule);

[0170] (vi) F(ab’)2, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin (i.e., a dimer of Fab’ fragments held together by two disulfide bonds);

[0171] (vii) Single domain antibodies or nanobodies are composed of a single VH or VL domains which exhibit sufficient affinity to the antigen; and

[0172] (viii) Fcab, a fragment of an antibody molecule containing the Fc portion of an antibody developed as an antigen-binding domain by introducing antigen-binding ability into the Fc region of the antibody.

[0173] Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).

[0174] Exemplary methods for generating antibodies employ induction of in-vivo production of antibody molecules, screening of immunoglobulin libraries (Orlandi D. R. et al., 1989. Proc. Natl. Acad. Sci. U. S. A. 86:3833-3837; Winter G. et al., 1991. Nature 349:293-299) or generation of monoclonal antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the Epstein-Barr virus (EBV)-hybridoma technique (Kohler G. et al., 1975. Nature 256:495-497; Kozbor D. et al., 1985. J. Immunol. Methods 81:31-42; Cote RJ. et al., 1983. Proc. Natl. Acad. Sci. U. S. A.

[0175] 80:2026-2030; Cole SP. et al., 1984. Mol. Cell. Biol. 62:109-120).

[0176] In cases where target antigens are too small to elicit an adequate immunogenic response when generating antibodies in-vivo, such antigens (haptens) can be coupled to antigenically neutral carriers such as keyhole limpet hemocyanin (KLH) or serum albumin [e.g., bovine serum albumine (BSA)] carriers (see, for example, US. Pat. Nos. 5,189,178 and 5,239,078]. Coupling a hapten to a carrier can be effected using methods well known in the art. For example, direct coupling to amino groups can be effected and optionally followed by reduction of the imino linkage formed. Alternatively, the carrier can be coupled using condensing agents such as dicyclohexyl carbodiimide or other carbodiimide dehydrating agents. Linker compounds can also be used to effect the coupling; both homobifunctional and heterobifunctional linkers are available from Pierce Chemical Company, Rockford, Ill. The resulting immunogenic complex can then be injected into suitable mammalian subjects such as mice, rabbits, and the like. Suitable protocols involve repeated injection of the immunogen in the presence of adjuvants according to a schedule which boosts production of antibodies in the serum. The titers of the immune serum can readily be measured using immunoassay procedures which are well known in the art.

[0177] The antisera obtained can be used directly or monoclonal antibodies may be obtained as described hereinabove.

[0178] Antibody fragments according to some embodiments of the invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment.

[0179] Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groupsresulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U. S. Pat. Nos.

[0180] 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. R. [Biochem. J. 73: 119-126 (1959)]. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent lightheavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

[0181] As described hereinabove, Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar et al. [Proc. Nat'l Acad. Sci. USA 69:2659-62 (1972)]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by [Whitlow and Filpula, Methods 2: 97-105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio / Technology 11:1271-77 (1993); and U. S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.

[0182] Another form of an antibody fragment is a peptide coding for a single complementaritydetermining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry [Methods, 2: 106-10 (1991)].

[0183] As mentioned, the antibody fragment may comprise a Fc region of an antibody termed “Fcab”. Such antibody fragments typically comprise the CH2-CH3 domains of an antibody. Fcabs are engineering to comprise at least one modification in a structural loop region of the antibody, i.e. in a CH3 region of the heavy chain. Such antibody fragments can be generated, for example, as follows: providing a nucleic acid encoding an antibody comprising at least one structural loop region (e.g. Fc region), modifying at least one nucleotide residue of the at least one structural loop regions, transferring the modified nucleic acid in an expression system, expressing the modifiedantibody, contacting the expressed modified antibody with an epitope, and determining whether the modified antibody binds to the epitope. See, for example, U. S. Patent Nos. 9,045,528 and 9,133,274 incorporated herein by reference in their entirety.

[0184] Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab').sub.2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

[0185] Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U. S. Pat. No.

[0186] 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0187] Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Markset al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(l):86-95 (1991)]. Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U. S. Pat. Nos.

[0188] 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio / Technology 10: 779-783 (1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).

[0189] Unless otherwise indicated, an immunoglobulin may be from any of the commonly known isotypes, including but not limited to IgA, secretory IgA, IgG and IgM. The IgG isotype is divided in subclasses in certain species: IgGl, IgG2, IgG3 and IgG4 in humans, and IgGl, IgG2a, IgG2b and IgG3 in mice. Immunoglobulins, e.g., human IgGl, exist in several allotypes, which differ from each other in at most a few amino acids.

[0190] According to a specific embodiment, the antibody is of an IgGl isotype. Once antibodies are obtained, they may be tested for activity, for example via ELISA, Western blotting, FACS, dot blot and any other method for antibody qualification.

[0191] As used herein a "multispecific antibody" is an antibody that can bind simultaneously to at least two targets that are of different structure, two different antigens or two different epitopes one on the intratumor T cells (at an immune checkpoint protein) and at least one another on a cDCl, as mentioned.

[0192] Specificity indicates how many antigens or epitopes an antibody is able to bind; i.e., bispecific, trispecific, quatraspecific. According to a specific embodiment, the antibody is a bispecific antibody.

[0193] Using these definitions, a natural antibody, e.g., an IgG, is bivalent because it has two binding arms but is monospecific because it binds to one epitope.

[0194] According to a specific embodiment, the Fc region of the antibody is modified to reduce binding specificity to an Fc receptor.

[0195] An " Fc receptor" or " FcR" is a receptor that binds to the Fc region of an immunoglobulin. FcRs that bind to an IgG antibody comprise receptors of the FcyR family, including allelic variantsand alternatively spliced forms of these receptors. The FcyR family consists of three activating (FcyRI, FcyRIII, and FcyRIV in mice; FcyRIA, FcyRIIA, and FcyRIIIA in humans) and one inhibitory (FcyRIIb, or equivalently RcyRIIB) receptor. Various properties of human FcyRs are summarized in US20170253659.

[0196] The majority of innate effector cell types co-express one or more activating FcyR and the inhibitory FcyRIIb, whereas natural killer (NK) cells selectively express one activating Fc receptor (FcyRIII in mice and FcyRIIIA in humans) but not the inhibitory FcyRIIb in mice and humans. Human IgGl binds to most human Fc receptors and is considered equivalent to murine IgG2a with respect to the types of activating Fc receptors that it binds to.

[0197] Contemplated mutations which reduce binding of the Fc region of the antibody to an Fc receptor are known in the art (Wang et al.. 2018, Protein Cell 9(1), 63-73 (2018)), These mutations include the " LALA mutation" described in Bruhns et al., 2009, BLOOD, vol. 113, no. 16, 2009, pages 3716 ■■ 25 and Hezareh et al., 2001, J. VIROL, vol. 75, no. 24, 2001, pages 12161 which involves substitution of the leucine residues at IMGT positions 1.3 and 1.2 of the CH2 domain with alanine (L1.3A and L1,2A). Thus, mutations in the CH2 domain of the Fc region at positions L235 and G237 (e.g. L235A and G237A) are contemplated. Alternatively, the generation of a-glycosyl antibodies through mutation of the conserved N- ■linked glycosylation site by mutating the aparagine (N) at IMGT position 84.4 of the CH2 domain to alanine, glycine or glutamine (N84.4A, N84.4G or N84.4Q) is also known to decrease IgGl effector function (Wang et al., 2018). As a further alternative, complement activation (Clq binding) and ADCC are known to be reduced through mutation of the proline at IMGT position 114 of the CH2 domain to alanine or glycine (P114A or Pl 14G) (Idusogie et ah, 2000, J. IMMUNOL., vol. 164, no. 8, 2000, pages 4178 ■■ 84; Klein et al., 2016, MABS, vol. 8, no. 6, 2016, pages 1010 - 1020). These mutations may also be combined in order to generate antibody molecules with further reduced or no ADCC or CDC activity.

[0198] A contemplated mutation in the CH3 domain of the Fc region is at position K447 (e.g. K447 deletion).

[0199] The mutated 4- IBB ligand may be linked to any portion of the antibody. In one embodiment, the linkage is a covalent linkage. Typically, in order not to interfere of binding of the antibody to its cognate target, the mutated 4- IBB ligand is linked to the Fc portion of the antibody. The 4-1 BB ligand may be fused directly to the Fc portion of may be linked via a peptide linker.

[0200] The linker peptide typically is a flexible linker. Peptide linkers may be entirely artificial (e.g., comprising 2 to 20 amino acid residues independently selected from the group consisting of glycine, serine, asparagine, threonine and alanine) or adopted from naturally occurring proteins. An exemplary linker peptide is SEQ ID NO: 4.

[0201] According to a particular embodiment, each heavy chain of the antibody is linked to at least one monomer, two monomers or three monomers of the mutated 4- IBB ligand. Preferably, each heavy chain of the antibody is linked to a homotrimer of the mutated 4-1 BB ligand.

[0202] Exemplary amino acid sequences of heavy chains of antibodies which target PD-1 and which are linked to a mutated 4-1BB homotrimer are set forth in SEQ ID NOs: 25 or 26.

[0203] The present inventors further contemplate bispecific antibodies that can bind simultaneously to two targets which are of different structure, one on the intratumor T cells (e.g. at an immune checkpoint protein) and another binding specifically to 4- IBB, wherein the arm that binds to 4- IBB is mutated so as to reduces 4- IBB signaling by at least 50 fold and no more than 10,000 fold, as compared to the parent (wild-type) antibody.

[0204] Preferably, the mutated antibody arm reduces 4- IBB signaling by at least 50 fold, at least 100 fold, at least 200 fold, at least 500 fold, at least 1000 fold, at least 2000 fold, at least 3000 fold, at least 4000 fold or at least 5000 fold as compared to the wild-type non-mutated antibody. In one embodiment, the mutated antibody reduces 4- IBB signaling by no more than 10,000 fold or no more than 5,000 fold as compared to the wild-type parent antibody. Methods of measuring 4- IBB signaling are described herein above.

[0205] In one embodiment, the parent (wild-type) antibody is Urelumab.

[0206] Urelumab, also known as BMS-663513, is a fully humanized IgG4 mAb from Bristol-Myers Squibb, and is described in WO 2004 / 010947, US 6,887,673 and US 7,214,493.

[0207] The heavy chain CDRs of Urelumab may be mutated at the following positions: 34, 100, 104 and 106, wherein the numbering is according to the wild-type sequence of the heavy chain of Urelumab, as set forth in SEQ ID NO: 51.

[0208] Contemplated mutations include W34A, G100A, Y104G and / or W106Y.

[0209] The light chain CDRs of Urelumab may be mutated at the following positions: 32, 89, 93, 94, 95 and 98, wherein the numbering is according to the wild-type sequence of the light chain of Urelumab, as set forth in SEQ ID NO: 52.

[0210] Contemplated mutations include Y32A, Y32N, Q89G, N93G, W94G, P95G and / or L98G.

[0211] In order to produce the multispecific antibody of some embodiments of the invention, the present moieties may be modified at the Fc region e.g., the CH3 domain (according to kabat) as well known in the art. Such a modification ensures correct assembly of the multispecific antibody via the heavy chains.

[0212] Accordingly, the CH3 domain of one heavy chain is altered, so that within the original interface the CH3 domain of one heavy chain that meets the original interface of the CH3 domain of the other heavy chain within the multispecific antibody, an amino acid residue is replaced withan amino acid residue having a larger side chain volume, thereby generating a protuberance within the interface of the CH3 domain of one heavy chain which is positionable in a cavity within the interface of the CH3 domain of the other heavy chain; and the CH3 domain of the other heavy chain is altered, so that within the original interface of the second CH3 domain that meets the original interface of the first CH3 domain within the trivalent, bispecific antibody an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the interface of the second CH3 domain within which a protuberance within the interface of the first CH3 domain is positionable (also known as “the knobs-into-holes” approach by Genentech).

[0213] According to a specific embodiment, the amino acid residue having a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), tryptophan (W).

[0214] According to a specific embodiment, the amino acid residue having a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), valine (V).

[0215] According to a specific embodiment, both CH3 domains are further altered by the introduction of cysteine (C) as amino acid in the corresponding positions of each CH3 domain such that a disulfide bridge between both CH3 domains can be formed.

[0216] In a specific embodiment, the bispecific comprises a T366W mutation in the CH3 domain of the "knobs chain" and T366S, L368A, Y407V mutations in the CH3 domain of the "hole chain". An additional interchain disulfide bridge between the CH3 domains can also be used (Merchant, A. M., et al., Nature Biotech 16 (1998) 677-681) e.g. by introducing a Y349C mutation into the CH3 domain of the "knobs chain" and a E356C mutation or a S354C mutation into the CH3 domain of the "hole chain". Thus in a another preferred embodiment, the bispecific antibody comprises Y349C, T366W mutations in one of the two CH3 domains and E356C, T366S, L368A, Y407V mutations in the other of the two CH3 domains or the bispecific antibody comprises Y349C, T366W mutations in one of the two CH3 domains and S354C, T366S, L368A, Y407V mutations in the other of the two CH3 domains (the additional Y349C mutation in one CH3 domain and the additional E356C or S354C mutation in the other CH3 domain forming a interchain disulfide bridge) (numbering always according to EU index of Kabat). But also other knobs-in-holes technologies as described by EP 1 870459A1, can be used alternatively or additionally. A specific example for the bispecific antibody are R409D; K370E mutations in the CH3 domain of the "knobs chain" and D399K; E357K mutations in the CH3 domain of the "hole chain" (numbering always according to EU index of Kabat).

[0217] In another embodiment the bispecific antibody comprises a T366W mutation in the CH3 domain of the "knobs chain" and T366S, L368A, Y407V mutations in the CH3 domain of the "hole chain" and additionally R409D; K370E mutations in the CH3 domain of the "knobs chain" and D399K; E357K mutations in the CH3 domain of the "hole chain".

[0218] In another embodiment the bispecific antibody comprises Y349C, T366W mutations in one of the two CH3 domains and S354C, T366S, L368A, Y407V mutations in the other of the two CH3 domains or the bispecific antibody comprises Y349C, T366W mutations in one of the two CH3 domains and S354C, T366S, L368A, Y407V mutations in the other of the two CH3 domains and additionally R409D; K370E mutations in the CH3 domain of the "knobs chain" and D399K; E357K mutations in the CH3 domain of the "hole chain".

[0219] According to a specific embodiment, S354C / T366W mutations are introduced for the 1st mAb (e.g., anti PD-1) and Y349C / T366S / L368A / Y407V mutations are introduced for the 2nd mAb (e.g., anti 4- IBB).

[0220] Alternatively or additionally, for correct heavy-light chain pairing, at least one of the moieties can be expressed in the CrossMab format (CH1-CL swapping).

[0221] The basis of the CrossMab technology is the crossover of antibody domains within one arm of a bispecific IgG antibody enabling correct chain association, whereas correct heterodimerization of the heavy chains can be achieved by the knob-into-hole technology as described above or charge interactions. This can be achieved by exchange of different domains within a Fab-fragment. Either the Fab domains (in the CrossMabFabformat), or only the variable VH-VL domains (CrossMabVH“VLformat) or the constant CH1-CL domains (CrossMabCH1 CLformat) within the Fab-fragment can be exchanged for this purpose. Indeed, for the CrossMabCH1 CLformat the respective original light chain and the novel VL-CH1 light chain do not result in undesired interactions with the respective original and VH-CL containing heavy chains, and no theoretical side products can be formed. In contrast, in the case of the CrossMabFabformat a non-functional monovalent antibody (MoAb) as well as a non-functional Fab-fragment can be formed. These side products can be removed by chromatographic techniques. In the case of the CrossMabVH VLformat an undesired side product with a VE-CH1 / VE-CE domain association known from Bence-Jones proteins can occur between the VE-CH1 containing heavy chain and the original unmodified VE-CE light chain. The introduction of repulsive charge pairs based on existing conserved charge pairs in the wildtype antibody framework into the constant CHI and CL domains of the wildtype non-crossed Fab-fragment can overcome the formation of this Bence-Jones-like side product in the CrossMabVH“VL+ / “ format. More details on CrossMab Technology can be found in Klein et al. Methods 154, 1 February 2019, Pages 21-31c.

[0222] Alternatively, multispecific e.g., bispecific antibodies described herein can be prepared by conjugating the moieties using methods known in the art. For example, each moiety of the multispecific antibody can be generated separately and then conjugated to one another. A variety of coupling or cross-linking agents can be used for covalent conjugation. Examples of crosslinking agents include protein A, carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohaxane-1-carboxylate (sulfo-SMCC) (see e.g., Karpovsky et al. (1984) J. Exp. Med. 160:1686; Liu, M A et al. (1985) Proc. Natl. Acad. Sci. (USA) 82:8648). Other methods include those described in Paulus (1985) Behring Ins. Mitt. No. 78, 118-132; Brennan et al. (1985) Science 229:81-83), and Glennie et al. (1987) J. Immunol. 139: 2367-2375). Preferred conjugating agents are SATA and sulfo-SMCC, both available from Pierce Chemical Co. (Rockford, Ill.).

[0223] Alternatively or additionally, the conjugation of each moiety of the multispecific antibody can be done via sulfhydryl bonding of the C-terminus hinge regions of the two heavy chains. In a specific embodiment, the hinge region is modified to contain an odd number of sulfhydryl residues, preferably one, prior to conjugation.

[0224] The antibodies described herein (both bispecific or the PD- 1-4- IBB ligand-based antibodies) may be attached to cytotoxic agents.

[0225] As used herein, the term “cytotoxic agent” refers to refers to a substance that inhibits or prevents the function of cells and / or causes destruction of cells. The term is intended to include radioactive isotopes (e.g.,211At,131I,125I,32P,35S and radioactive isotopes of Lu, including177Lu,86Y,90Y,inIn,177LU,225AC,212Bi,213Bi,66Ga,67Ga,68Ga,64Cu,67Cu,71As,72As,76As,77As,65Zn,48V,203Pb,209Pb,212Pb,166HO,149Pm,153Sm,2O1T1,188Re,186Re and "mTc), anticancer agents as otherwise described herein, including chemotherapeutic (anticancer drugs e.g. methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), taxol, doxoruicin, cisplatin, 5-fluorouridine, melphalan, ethidium bromide, mitomycin C, chlorambucil, daunorubicin and other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, therapeutic RNA molecules (e.g., siRNA, antisense oligonucleotides, microRNA, ribozymes, RNA decoys, aptamers), DNAzymes, antibodies, proteins and polynucleotides encoding same, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, such as pokeweed antiviral protein (PAP), ricin toxin A, abrin, gelonin, saporin, cholera toxin A, diphtheria toxin, Pseudomonas exotoxin, and alpha-sarcin, including fragments and / or variants thereof.

[0226] Another aspect described herein pertains to nucleic acid molecules that encode the antibodies described herein. The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form. A nucleic acid is "isolated" or "rendered substantially pure" when purified away from other cellular components or other contaminants, e.g., other cellular nucleic acids (e.g., other chromosomal DNA, e.g., the chromosomal DNA that is linked to the isolated DNA in nature) or proteins, by standard techniques, including alkaline / SDS treatment, CsCl banding, column chromatography, restriction enzymes, agarose gel electrophoresis and others well known in the art. See, F. Ausubel, et al, ed. (1987) Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York. A nucleic acid described herein can be, for example, DNA or RNA and may or may not contain intronic sequences. In a certain embodiments, the nucleic acid is a cDNA molecule.

[0227] Exemplary nucleic acids contemplated by the present invention are at least 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99% or 100 % identical to those set forth in SEQ ID NOs:27-42.

[0228] Nucleic acids described herein can be obtained using standard molecular biology techniques. For antibodies expressed by hybridomas {e.g., hybridomas prepared from transgenic mice carrying human immunoglobulin genes as described further below), cDNAs encoding the light and heavy chains of the antibody made by the hybridoma can be obtained by standard PCR amplification or cDNA cloning techniques. For antibodies obtained from an immunoglobulin gene library (e.g., using phage display techniques), nucleic acid encoding the antibody can be recovered from the library.

[0229] Once DNA fragments encoding VH and VL segments are obtained, these DNA fragments can be further manipulated by standard recombinant DNA techniques, for example to convert the variable region genes to full-length antibody chain genes, to Fab fragment genes or to a scFv gene. In these manipulations, a VL- or Vn-encoding DNA fragment is operatively linked to another DNA fragment encoding another protein, such as an antibody constant region or a flexible linker. The term "operatively linked", as used in this context, is intended to mean that the two DNA fragments are joined such that the amino acid sequences encoded by the two DNA fragments remain inframe.

[0230] The isolated DNA encoding the VH region can be converted to a full-length heavy chain gene by operatively linking the VH-encoding DNA to another DNA molecule encoding heavy chain constant regions (hinge, CHI, CH2 and / or CH3). The sequences of human heavy chain constant region genes are known in the art (see e.g., Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U. S. Department of Health and Human Services,NIH Publication No. 91-3242) and DNA fragments encompassing these regions can be obtained by standard PCR amplification. The heavy chain constant region can be an IgGl, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant region, for example, an IgGl region. For a Fab fragment heavy chain gene, the VH-encoding DNA can be operatively linked to another DNA molecule encoding only the heavy chain CHI constant region.

[0231] The isolated DNA encoding the VL region can be converted to a full-length light chain gene (as well as a Fab light chain gene) by operatively linking the VE-encoding DNA to another DNA molecule encoding the light chain constant region, CL. The sequences of human light chain constant region genes are known in the art (see e.g., Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U. S. Department of Health and Human Services, NIH Publication No. 91-3242) and DNA fragments encompassing these regions can be obtained by standard PCR amplification. The light chain constant region can be a kappa or lambda constant region.

[0232] A variety of prokaryotic or eukaryotic cells can be used as host-expression systems to express the antibodies of some embodiments of the invention. These include, but are not limited to, microorganisms, such as bacteria transformed with a recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vector containing the coding sequence; yeast transformed with recombinant yeast expression vectors containing the coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors, such as Ti plasmid, containing the coding sequence. Mammalian expression systems can also be used to express the antibodies of some embodiments of the invention. Conditions of expression in culture depend on the expression system used.

[0233] Recovery of the antibody from the culture is effected following an appropriate time in the culture. The phrase "recovering the recombinant antibody” refers to collecting the whole fermentation medium containing the antibody and need not imply additional steps of separation or purification. Notwithstanding the above, antibodies of some embodiments of the invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization.

[0234] The antibodies (including the PD-1-4-1BB ligand-based antibodies), antibody compositions and methods described herein have numerous in vitro and in vivo utilities involving, for example, forming a physical bridge between PD-1+ T cells and cells expressing 4-1BB. In apreferred embodiment, the antibodies described herein are human or humanized antibodies. For example, the antibodies described herein can be administered to cells in culture, in vitro or ex vivo, or to subjects, e.g., in vivo, to enhance immunity in a variety of diseases including but not limited to cancer.

[0235] As used herein, the term “subject” includes mammals, such as human beings at any age which suffer from a disorder, e.g., cancer. According to a specific embodiment, this term encompasses individuals who are at risk to develop the disorder.

[0236] In a preferred embodiment, the subject is a tumor-bearing subject and an immune response against the tumor is enhanced. A tumor may be a solid tumor or a liquid tumor, e.g., a hematological malignancy. In certain embodiments, a tumor is an immunogenic tumor. In certain embodiments, a tumor is non-immunogenic. In certain embodiments, a tumor is PD-1 positive.

[0237] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated malignant cell growth.

[0238] Examples of cancers that can be analyzed and treated according to some embodiments of the invention, include, but are not limited to, tumors of the gastrointestinal tract (colon carcinoma, rectal carcinoma, colorectal carcinoma, colorectal cancer, colorectal adenoma, hereditary nonpolyposis type 1, hereditary nonpolyposis type 2, hereditary nonpolyposis type 3, hereditary nonpolyposis type 6; colorectal cancer, hereditary nonpolyposis type 7, small and / or large bowel carcinoma, esophageal carcinoma, tylosis with esophageal cancer, stomach carcinoma, pancreatic carcinoma, pancreatic endocrine tumors), endometrial carcinoma, dermatofibrosarcoma protuberans, gallbladder carcinoma, Biliary tract tumors, prostate cancer, prostate adenocarcinoma, renal cancer (e.g., Wilms’ tumor type 2 or type 1), liver cancer (e.g., hepatoblastoma, hepatocellular carcinoma, hepatocellular cancer), bladder cancer, embryonal rhabdomyosarcoma, germ cell tumor, trophoblastic tumor, testicular germ cells tumor, immature teratoma of ovary, uterine, epithelial ovarian, sacrococcygeal tumor, choriocarcinoma, placental site trophoblastic tumor, epithelial adult tumor, ovarian carcinoma, serous ovarian cancer, ovarian sex cord tumors, cervical carcinoma, uterine cervix carcinoma, small-cell and non-small cell lung carcinoma, nasopharyngeal, breast carcinoma (e.g., ductal breast cancer, invasive intraductal breast cancer, sporadic; breast cancer, susceptibility to breast cancer, type 4 breast cancer, breast cancer- 1, breast cancer-3; breast-ovarian cancer), squamous cell carcinoma (e.g., in head and neck), neurogenic tumor, astrocytoma, ganglioblastoma, neuroblastoma, lymphomas (e.g., Hodgkin's disease, non-Hodgkin's lymphoma, B cell, Burkitt, cutaneous T cell, histiocytic, lymphoblastic, T cell, thymic), gliomas, adenocarcinoma, adrenal tumor, hereditary adrenocortical carcinoma, brain malignancy (tumor), various other carcinomas (e.g., bronchogenic large cell,ductal, Ehrlich-Lettre ascites, epidermoid, large cell, Lewis lung, medullary, mucoepidermoid, oat cell, small cell, spindle cell, spinocellular, transitional cell, undifferentiated, carcinosarcoma, choriocarcinoma, cystadenocarcinoma), ependimoblastoma, epithelioma, erythroleukemia (e.g., Friend, lymphoblast), fibrosarcoma, giant cell tumor, glial tumor, glioblastoma (e.g., multiforme, astrocytoma), glioma hepatoma, heterohybridoma, heteromyeloma, histiocytoma, hybridoma (e.g., B cell), hypernephroma, insulinoma, islet tumor, keratoma, leiomyoblastoma, leiomyosarcoma, lymphosarcoma, melanoma, mammary tumor, mastocytoma, medulloblastoma, mesothelioma, metastatic tumor, monocyte tumor, multiple myeloma, myelodysplastic syndrome, myeloma, nephroblastoma, nervous tissue glial tumor, nervous tissue neuronal tumor, neurinoma, neuroblastoma, oligodendroglioma, osteochondroma, osteomyeloma, osteosarcoma (e.g., Ewing's), papilloma, transitional cell, pheochromocytoma, pituitary tumor (invasive), plasmacytoma, retinoblastoma, rhabdomyosarcoma, sarcoma (e.g., Ewing's, histiocytic cell, Jensen, osteogenic, reticulum cell), schwannoma, subcutaneous tumor, teratocarcinoma (e.g., pluripotent), teratoma, testicular tumor, thymoma and trichoepithelioma, gastric cancer, fibrosarcoma, glioblastoma multiforme; multiple glomus tumors, Li-Fraumeni syndrome, liposarcoma, lynch cancer family syndrome II, male germ cell tumor, mast cell leukemia, medullary thyroid, multiple meningioma, endocrine neoplasia myxosarcoma, paraganglioma, familial nonchromaffin, pilomatricoma, papillary, familial and sporadic, rhabdoid predisposition syndrome, familial, rhabdoid tumors, soft tissue sarcoma, and Turcot syndrome with glioblastoma.

[0239] According to a specific embodiment, the cancer is melanoma.

[0240] According to a specific embodiment, the cancer is a solid tumor (lung cancer, liver cancer, ovarian cancer, gastric cancer and breast cancer).

[0241] According to a specific embodiment, the cancer is a primary tumor.

[0242] According to a specific embodiment, the cancer is metastatic.

[0243] According to a specific embodiment, the cancer is a secondary tumor.

[0244] According to a specific embodiment, the lung cancer is non- small cell lung cancer.

[0245] According to a specific embodiment, the lung cancer is small cell lung cancer.

[0246] According to a specific embodiment, the liver cancer is Hepatocellular carcinoma.

[0247] Treatment can be combined with any anti-cancer treatment known in the art, including, but not limited to, chemotherapeutic agents, radio therapeutic agents, hormonal therapy, immune modulators, engineered immune cell therapy (e.g., CAR-T) and other treatment regimens (e.g., surgery, cell transplantation e.g. hematopoietic stem cell transplantation) which are well known in the art.

[0248] The chemotherapeutic agent of the present invention can be, but not limited to, cytarabine (cytosine arabinoside, Ara-C, Cytosar-U), asprin, sulindac, curcumin, alkylating agents including: nitrogen mustards, such as mechlor-ethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU); thylenimines / methylmelamine such as thriethylenemelamine (TEM), triethylene, thiophosphoramide (thiotepa), hexamethylmelamine (HMM, altretamine ); alkyl sulfonates such as busulfan; triazines such as dacarbazine (DTIC); antimetabolites including folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5-fluorouracil, fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine ), 5-azacytidine, 2,2 • difluorodeoxycytidine, purine analogs such as 6-mercaptopurine, 6-thioguanine, azathioprine, 2 '-deoxycoformycin (pento statin), erythrohydroxynonyladenine (EHNA), fludarabine phosphate, and 2-chlorodeoxy adenosine (cladribine, 2-CdA); natural products including antimitotic drugs such as paclitaxel, vinca alkaloids including vinblastine (VLB), vincristine, and vinorelbine, taxotere, estramustine, and estramustine phosphate; epipodophylotoxins such as etoposide and teniposide; antibiotics, such as actimomycin D, daunomycin (rubidomycin), doxorubicin, mitoxantrone, idarubicin, bleomycins, plicamycin (mithramycin), mitomycinC, and actinomycin; enzymes such as L-asparaginase, cytokines such as interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, TNF-beta and GM-CSF, anti-angiogenic factors, such as angiostatin and endostatin, inhibitors of FGF or VEGF such as soluble forms of receptors for angiogenic factors, including soluble VGF / VEGF receptors, platinum coordination complexes such as cisplatin and carboplatin, anthracenediones such as mitoxantrone, substituted urea such as hydroxyurea, methylhydrazine derivatives including Nmethylhydrazine (MIH) and procarbazine, adrenocortical suppressants such as mitotane (o,p' -DDD) and aminoglutethimide; hormones and antagonists including adrenocorticosteroid antagonists such as prednisone and equivalents, dexamethasone and aminoglutethimide; progestin such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogen such as diethylstilbestrol and ethinyl estradiol equivalents; antiestrogen such as tamoxifen; androgens including testosterone propionate and fluoxymesterone / equivalents; antiandrogens such as flutamide, gonadotropin-releasing hormone analogs and leuprolide; non-steroidal antiandrogens such as flutamide; kinase inhibitors, histone deacetylase inhibitors, methylation inhibitors, proteasome inhibitors, monoclonal antibodies, oxidants, anti-oxidants, telomerase inhibitors, BH3 mimetics, ubiquitin ligase inhibitors, stat inhibitors and receptor tyrosin kinase inhibitors such as imatinib mesylate (marketed as Gleevac or Glivac) and erlotinib (an EGF receptor inhibitor) now marketed as Tarveca; and anti-virals such as oseltamivir phosphate, Amphotericin B, and palivizumab.

[0249] In some embodiments the chemotherapeutic agent of the present invention is cytarabine (cytosine arabinoside, Ara-C, Cytosar-U), quizartinib (AC220), sorafenib (BAY 43-9006), lestaurtinib (CEP-701), midostaurin (PKC412), carboplatin, carmustine, chlorambucil, dacarbazine, ifosfamide, lomustine, mechlorethamine, procarbazine, pentostatin, (2'deoxycoformycin), etoposide, teniposide, topotecan, vinblastine, vincristine, paclitaxel, dexamethasone, methylprednisolone, prednisone, all-trans retinoic acid, arsenic trioxide, interferon- alpha, rituximab (Rituxan®), gemtuzumab ozogamicin, imatinib mesylate, Cytosar-U), melphalan, busulfan (Myleran®), thiotepa, bleomycin, platinum (cisplatin), cyclophosphamide, Cytoxan®)., daunorubicin, doxorubicin, idarubicin, mitoxantrone, 5-azacytidine, cladribine, fludarabine, hydroxyurea, 6-mercaptopurine, methotrexate, 6-thioguanine, or any combination thereof.

[0250] According to a specific embodiment, the treatment is combined with PD- 1 antibodies or PDL-1 antibodies.

[0251] For example, when the PD-1 arm of the above disclosed antibodies is a non-blocking PD-1 antibody, the present inventors contemplate administration of a PD-1 blocking antibody or a

[0252] PDL-1 antibody.

[0253] Examples of PD-1 blocking antibodies are provided herein above.

[0254] Suitable PDL-1 antibodies comprise or are derived from an antibody selected from the group consisting of: (i) avelumab (MSB0010718C; human IgGl PDL-1 monoclonal antibody; Merck-Serono; described in WO 2013 / 079174, which is hereby incorporated into the present application by reference in its entirety); (ii) atezolizumab (MPDL3280A, RG7446; human IgG PDL-1 monoclonal antibody; Hoffmann-La Roche); (iii) MDX-1105 (BMS -936559; human IgG4 PDL-1 monoclonal antibody; Bristol-Myers Squibb; described in WO 2007 / 005874, which is hereby incorporated into the present application by reference in its entirety); (iv) durvalumab (MEDI4736; humanized IgGl PDL-1 monoclonal antibody; AstraZeneca; described in WO 2011 / 066389 and US 2013 / 034559, which are hereby incorporated into the present application by reference in their entirety); (v) KN035 (PDL-1 monoclonal antibody; 3D Medicines); (vi) LY3300054 (PDL-1 monoclonal antibody; Eli Lilly); and (vii) YW243.55.570 (described in WO 2010 / 077634 and U. S. Pat. No. 8,217,149, the entirety of each of which is incorporated herein by reference).

[0255] The additional agent may be provided in the same composition as the antibodies described herein (i.e. co-formulated in a single pharmaceutical composition) or administered as different compositions.

[0256] As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[0257] Herein the term "active ingredient" refers to the antibody accountable for the biological effect.

[0258] Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.

[0259] Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

[0260] Techniques for formulation and administration of drugs may be found in “Remington’s Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.

[0261] Suitable routes of administration may, for example, include topical, oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intraocular injections.

[0262] Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient. In one embodiment, the antibody may be administered directly into the tumor of the subject.

[0263] Pharmaceutical compositions of some embodiments of the invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, spray drying, coating or lyophilizing processes.

[0264] Pharmaceutical compositions for use in accordance with some embodiments of the invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the activeingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[0265] For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0266] For oral administration, the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and / or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0267] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0268] Pharmaceutical compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.

[0269] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0270] For administration by nasal inhalation, the active ingredients for use according to some embodiments of the invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0271] The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continues infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents.

[0272] Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

[0273] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.

[0274] The pharmaceutical composition of some embodiments of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

[0275] Pharmaceutical compositions suitable for use in context of some embodiments of the invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means anamount of active ingredients (antibody) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., cancer) or prolong the survival of the subject being treated.

[0276] Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

[0277] For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.

[0278] Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in " The Pharmacological Basis of Therapeutics", Ch. 1 P-l).

[0279] Dosage amount and interval may be adjusted individually to provide levels of the active ingredient are sufficient to induce or suppress the biological effect (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.

[0280] According to a specific embodiment, the dosing of the antibody described herien can be 0.1-100 mg / kg.

[0281] According to a specific embodiment, the dosing of the antibody can be 0.1-100 mg / kg. According to a specific embodiment, the dosing of the antibody can be 0.1-80 mg / kg. According to a specific embodiment, the dosing of the antibody can be 0.1-60 mg / kg. According to a specific embodiment, the dosing of the antibody can be 0.1-50 mg / kg. According to a specific embodiment, the dosing of the antibody can be 0.1-40 mg / kg. According to a specific embodiment, the dosing of the antibody can be 0.1-30 mg / kg. According to a specific embodiment, the dosing of the antibody can be 0.1-20 mg / kg. According to a specific embodiment, the dosing of the antibody can be 0.1-10 mg / kg. According to a specific embodiment, the dosing of the antibody can be 1-100 mg / kg. According to a specific embodiment, the dosing of the antibody can be 10-100 mg / kg. According to a specific embodiment, the dosing of the antibody can be 20-100 mg / kg. According to a specific embodiment, the dosing of the antibody can be 30-100 mg / kg. According to a specificembodiment, the dosing of the antibody can be 40-100 mg / kg. According to a specific embodiment, the dosing of the antibody can be 50-100 mg / kg. According to a specific embodiment, the dosing of the antibody can be 60-100 mg / kg. According to a specific embodiment, the dosing of the antibody can be 70-100 mg / kg.

[0282] According to a specific embodiment, the dosing of the antibody can be 1-20 mg / kg. According to a specific embodiment, the dosing of the antibody can be 1-15 mg / kg. According to a specific embodiment, the dosing of the antibody can be 1-10 mg / kg. According to a specific embodiment, the dosing of the antibody can be 1-5 mg / kg. According to a specific embodiment, the dosing of the antibody can be 2-20 mg / kg. According to a specific embodiment, the dosing of the antibody can be 4-20 mg / kg. According to a specific embodiment, the dosing of the antibody can be 6-20 mg / kg. According to a specific embodiment, the dosing of the antibody can be 8-20 mg / kg. According to a specific embodiment, the dosing of the antibody can be 10-20 mg / kg. According to a specific embodiment, the dosing of the antibody can be 12-20 mg / kg. According to a specific embodiment, the dosing of the antibody can be 15-20 mg / kg. According to a specific embodiment, the dosing of the antibody can be 18-20 mg / kg. According to a specific embodiment, the dosing of the antibody can be 1-5 mg / kg. According to a specific embodiment, the dosing of the antibody can be 2-10 mg / kg. According to a specific embodiment, the dosing of the antibody can be 5-10 mg / kg.

[0283] Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

[0284] The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

[0285] Compositions of some embodiments of the invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit or article of manufacture, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U. S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparationof the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above. In the article of manufacture comprising the polypeptide described herein and the additional antibody (i.e. PD-1 blocking antibody or PDL-1 antibody), each of the agents may be packaged separately in individual packaging.

[0286] As used herein the term “about” refers to ± 10 %.

[0287] The terms "comprises", "comprising", "includes", "including", “having” and their conjugates mean "including but not limited to".

[0288] The term “consisting of’ means “including and limited to”.

[0289] The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and / or parts, but only if the additional ingredients, steps and / or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.

[0290] As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.

[0291] Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0292] Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging / ranges between” a first indicate number and a second indicate number and “ranging / ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

[0293] As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques andprocedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

[0294] When reference is made to particular sequence listings, such reference is to be understood to also encompass sequences that substantially correspond to its complementary sequence as including minor sequence variations, resulting from, e.g., sequencing errors, cloning errors, or other alterations resulting in base substitution, base deletion or base addition, provided that the frequency of such variations is less than 1 in 50 nucleotides, alternatively, less than 1 in 100 nucleotides, alternatively, less than 1 in 200 nucleotides, alternatively, less than 1 in 500 nucleotides, alternatively, less than 1 in 1000 nucleotides, alternatively, less than 1 in 5,000 nucleotides, alternatively, less than 1 in 10,000 nucleotides.

[0295] It is understood that any Sequence Identification Number (SEQ ID NO) disclosed in the instant application can refer to either a DNA sequence or a RNA sequence, depending on the context where that SEQ ID NO is mentioned, even if that SEQ ID NO is expressed only in a DNA sequence format or a RNA sequence format. Similarly, though some sequences are expressed in a RNA sequence format (e.g., reciting U for uracil), depending on the actual type of molecule being described, it can refer to either the sequence of a RNA molecule comprising a dsRNA, or the sequence of a DNA molecule that corresponds to the RNA sequence shown. In any event, both DNA and RNA molecules having the sequences disclosed with any substitutes are envisioned.

[0296] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

[0297] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

[0298] EXAMPLES

[0299] Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non-limiting fashion.

[0300] Generally, the nomenclature used herein, and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques.

[0301] GENERAL MATERIALS AND METHODS

[0302] Mice

[0303] C57BL / 6 mice were purchased from Envigo. C57BL / 6 h4-lBB, C57BL / 6 h4-lBB hPD-1 and C57BL / 6 h4-lBB hPD-1 hPDL-1 mice were purchased from Biocytogen. All animals were bred and housed at the Weizmann Institute of Science specific-pathogen-free facility in individually ventilated cages, with a standard 12 / 12-h dark / light cycle at 22 °C ambient temperature and 50% humidity. For all in vivo experiments, animals of both sexes were used between the ages of 8 and 10 weeks, randomized and assigned to experimental groups.

[0304] Tumor challenge and treatment

[0305] Tumor cell lines were maintained in a humidified incubator at 37 °C and 5% CO2, and cultured in complete RPMI medium containing 25 mM HEPES, 1% L-glutamine, 10% FBS, 1% Pen / Strep, 1% nonessential amino acids and 1% pyruvate. MC38 (2 × 106), B16-F10 (2.5 x1051:1 Matrigel, Corning), and MCA-205 (5xl05), were implanted subcutaneously in the right flank of mice, and tumor volumes measured every 2-3 days by electronic caliper. The researcher performing the measurements was blinded to the treatment status of the mice. Volume was calculated using the formula (L22× L1) / 2, where L1and L2represent the longest and shortest diameter, respectively. When the sum of tumor length and width reached approximately 80 mm3(10-14 days after tumor inoculation), mice were randomized by tumor size (day 0) and treated 3 times every 3 days by intraperitoneal injection with in-house produced PD-1 4-1 BBL chimeras as described for each experiment. Mice were monitored for 8-60 days after treatment initiation, or euthanized around day 20 for liver immune-phenotyping or until the majority of the untreated control group was sacrificed due to limitations on tumor size (1,500 mm3) imposed by the Weizmann Institute of Science Institutional Animal Care and Use Committee. Tumor-free mice were defined as mice with complete response and rejection of the primary tumor that had no tumor re-occurrence for 60 days after the treatment onset. For the re-challenge experiments, tumor-free mice were re-inoculated with MC38 tumor cells (2×106) into the contrary flank.

[0306] Liver tissue processing for flow cytometry

[0307] Perfused livers were cut into small fragments and placed in GentleMACS C tubes with 1 mg ml-1Collagenase D (Roche). Tubes were incubated (37 °C, 25 r.p.m. for 30 min, twice) with a dissociation cycle in the GentleMACS Octo Dissociator before each incubation, followed bythree washes with PBS, centrifugation at 1,500 r.p.m. and retrieval of the supernatant, omitting the parenchymal cell pellet. The cell fraction was then incubated for 5 min with red blood cell lysis buffer. The sample was then subjected to a series of gradient centrifugations until the desired single-cell suspension was obtained containing mainly immune cells.

[0308] Flow cytometry

[0309] Single-cell suspensions were prepared as described above. For surface staining, cells were plated in U-shaped 96-well plates (ThermoFisher) at a concentration of 0.2–1 × 106cells in 100 µl of PBS. All subsequent steps were performed in the dark. Cells were first stained with LIVE / DEAD Fixable blue dead cell stain (ThermoFisher) followed by two washes with PBS, resuspended in 25 µl of FACS buffer with mouse TruStain Fc block (BioLegend) and incubated for 15 min at RT. Surface antigens were stained in FACS buffer for 30 min on ice at a concentration of 1 µg / ml. Then, cells were washed twice with FACS buffer, resuspended in 150 µl of FACS buffer and analyzed by flow cytometry. All samples were analyzed on a CytoFLEX LX (Beckman Coulter). Cell populations were defined by the following markers (BioLegend): CD4+ T cells: CD45+ CD3+ CDllb- CD4+, CD8+ T cells: CD45+ CD3+ CDllb- CD8+, regulatory T cells: CD45+ CD3+ CD1 lb- CD4+ FoxP3+, Kupffer cell and non- Kupffer cell macrophages were gated using the following surface markers: CD45, MHC II, CD1 lb, CD 11c, CD64, F4 / 80, Ly6C, Tim4 and CX3CR1.

[0310] Transaminase serum levels and H& E staining

[0311] Mice were treated by intraperitoneal injection of 100 ug of RMP-14-4- 1BBL with different variants at day 0,3,6 at day 7 (24h post last treatment), peripheral blood was collected into clot activator serum tubes (Becton Dickinson). Blood was allowed to clot at RT for 30 min and then centrifuged at 3,500 r.p.m. for 10 min. Serum transaminase (ALT / AST) levels were determined by a commercial laboratory (American Medical Laboratories). Livers from treated animals were harvested and placed in 4% paraformaldehyde overnight, then paraffin processed and stained with hematoxylin and eosin (H& E) at the Histology & Pathology unit of the Weizmann Institute. Slides were scanned using a Pannoramic scan II scanner (3DHISTECH), and images were obtained with Case Viewer software.

[0312] Statistics and reproducibility

[0313] Flow cytometry data analysis was performed using FlowJo v.10.6.2; all other data analyses were performed using GraphPad Prism (GraphPad Software). Quantitative data are presented as means ± s.e.m. Mouse numbers were taken into consideration for in vivo studies to ensure that biological effects would be detected, and to enable comparison between groups, and were determined based on results of preliminary experiments. Group allocation was randomized for allin vivo experiments as described above. Tumor measurements were performed blindly; for other in vivo and in vitro studies the researchers were not blinded to treatment group when performing the experiments. For each dataset, normality of the population and / or population residuals (Gaussian distribution) was confirmed using Shapiro-Wilk and / or D’Agostino-Pearson testing. For normal distributions, one-way analysis of variance (ANOVA) with Tukey’s post hoc test was used to compare all groups with three or more treatments. When two groups were compared, an unpaired two-tailed Student’s / -test (two-tailed, unequal variance) was used to determine statistical significance. When data were not normally distributed, a nonparametric test was used — Kruskal- Wallis with Dunn’s post hoc test for multiple comparisons or Mann-Whitney test when two groups were compared. P<0.05 was considered as significant in all statistical tests and is represented in figures as follows: *P<0.05, **P< 0.01, ***P< 0.001, ****P < 0.0001.

[0314] EXAMPLE 1

[0315] Rational for the development ofPD-1 targeted 4-1BB therapy

[0316] The synergistic effect of aPD-1 a4-lBB combinational treatment was evaluated as a proof of concept for the development of a4-lBB / aPD-l monoclonal antibodies (mAbs) treatments. MC-38 tumor bearing mice were treated with a4-lBB (with 3H3 or LOB 12.3 clones) alone or in combination with aPD-1 (RMP 1.14 clone). aPD-1 +a4-lBB antibody combination treatment both with 3H3 and LOB 12.3 clones significantly improved anti-tumor activity compared to either 4-1BB monotherapy or PD-1 monotherapy alone (Figure 1A-B). Next, liver immune infiltration was evaluated following aPD-l+a4-lBB treatment as a sign of liver toxicity. H& E staining confirmed immune cell infiltration with both 4- IBB clones as well as in combination treatments. (Figure 1D). Combination treatment promoted T cell immune infiltration, both CD4+ and CD8+, but this increase was not higher than that seen with 4- IBB monotherapy. Importantly aPD-1 alone did not promote CD4 T cell infiltration in the liver (although a slight CD8 T cell elevation was observed, it was not statistically significant) suggesting that aPD-1 plays a synergistic role when combined with a4-lBB treatment without exacerbating a4-lBB toxicity profile. The literature suggests Kupffer cells (KCs) to play a role in 4- IBB mediated liver toxicity. Here, percentages of KCs remained unaffected by aPD-1 therapy, a4-lBB therapy or their combination (Figure 1C).

[0317] EXAMPLE 2

[0318] Development of 4-1 BBL chimeras

[0319] In order to mitigate 4- IBB -mediated liver toxicity while preserving potent anti-tumor activity and leveraging the synergistic effects of PD-1 and 4- IBB therapy, the present inventorsdeveloped a molecule capable of activating 4-1BB exclusively on PD-l-positive T cells. This was achieved through the generation of a PD- 1-4- IBB ligand-based approach. The molecule comprised human 4-1BBL monomers attached through a linker to mAb with a LALA mutation to prevent Fc receptor binding (Figure 2A). Untargeted antibody (anti-human DNAse clone; 1H3)-chimeric molecule (1H3-LALA-4-1BBL) was generated to solely target human 4-1BB. This molecule was tested in a 4- IBB humanized mouse model, comparing its anti-tumor activity to Urelumab, the clinical human 4-lBB-hIgG4 antibody. Both 1H3-LALA-4-1BBL and Urelumab demonstrated potent anti-tumor activity in the MC-38 model (Figures 2B and 2C). However, on day 7 (1 day post the last injection), both 4-1BBL and Urelumab induced elevated serum ALT levels. Upon profiling liver lymphoid cells on day 20, increased CD4+ T cells in both 4-1BBL and Urelumab-treated livers was observed. Interestingly, while Urelumab promoted significant CD8+ T cell infiltration in the liver, 4-1BBL did not (Figure 2E). Given the lack of improvement in liver toxicity with 4-1BBL, the present inventors generated a PD-l-targeted 4-1BBL molecule (RMP1.14-4-1BBL) to direct 4-1BBL signaling to PD-1+ cells (Figure 2F). In subsequent experiments, RMP1.14-4-1BBL showed potent anti-tumor activity in the MC-38 model, but 1H3-4-1BBL exhibited superior efficacy (Figures 2G, 2H, 21). Unexpectedly, RMP1.14-4-1BBL led to higher ALT levels than 1H3-4-1BBL (Figure 2J).

[0320] EXAMPLE 3

[0321] Fine-tuning to find the optimal attenuation level for PD-1-4-1BBL

[0322] To address liver toxicity, point mutations were introduced to attenuate the 4-1BBL arm and reduce its binding affinity to its target. RMP1-14-14-BBL was synthesized with V100K mutation which led to a 15-fold attenuation (Figure 3A). This mutation did not compromise its anti-tumor activity however ALT levels remained elevated (Figure 3B and 3C). Similar results were observed with the V152K mutation, which induced a 40-fold attenuation (Figure 3D, 3E and 3F). The 4-1BBL arm was further attenuated by introducing V100K_L115D mutations (~20, 000-fold attenuation), (Figure 3M) but while this reduced toxicity, it compromised the ligand’s antitumor efficacy (Figure 3N and 30). Next, the V152L mutation was introduced (~ 150-fold attenuation) (Figure 3G), which promoted robust anti-tumor activity without elevating ALT levels (Figures 3H and 31) or inducing CD8+ T cell infiltration in the liver (Figure 4C). To refine the attenuation level further, the present inventors tested L115D-V100H (~2000-fold attenuation) (Figure 3 J) its anti-tumor activity remained potent with no signs of liver toxicity (Figures 3K and 3L) though slightly inferior, anti-tumor efficacy compared to the WT or V152L variants (Figure 3P). 4- IBB potency of RMP1-14-4-1BBL-V152L was rescued in reporter assay of cells expressing stable mPD-1 and h4-lBB. (Figure 3Q).

[0323] Next, the selected optimal PD-1 / 4-1BBL, RMP1.14 / 4-1BBL V152L was compared to Urelumab N297Q, the human antibody that entered clinical trials that showed potent efficacy but strong liver toxicity. Strikingly, although the selected PD-1 / 4-1BBL comprised a 260 fold attenuation to the 4-1BBL arm, it still demonstrated comparable anti-tumor activity to Urelumab N297Q (Figures 4A and 4D) without any signs of liver toxicity, as indicated by the absence of ALT elevation (Figure 4B) and CD8 T cell infiltration (Figure 4C).

[0324] Additionally, to confirm that the selected molecule benefits from PD-1 targeting and that the anti-tumor activity and toxicity are not solely attributed to 4-1BBL, the anti-tumor activity and toxicity of RMP1-14 / 4-1BBL V152L was compared to its untargeted counterpart, 1H3 / 4-1BBL V152L. The results demonstrated that the selected 4-1BBL with V152L mutation requires PD-1 targeting, as 1H3 / 4-1BBL V152L loses anti-tumor activity in MC-38 tumor bearing mice (Figures 4E and 4F). Similarly, no anti-tumor activity also correlated with no ALT elevation (Figure 4G). However, once again RMP1-14 / 4-1BBL V152L demonstrated potent anti-tumor activity with no liver toxicity.

[0325] In summary, to address liver toxicity, various point mutations were introduced to attenuate the 4-1BBL arm, resulting in a balance between reduced toxicity and maintaining anti-tumor efficacy, with the V152L mutation achieving robust anti-tumor activity while sparing liver toxicity.

[0326] EXAMPLE 4

[0327] PD-1 blocking requirement for PD-1-4-1 BBL therapy

[0328] The V152L mutant was selected as the optimal attenuated 4-1BB ligand for the anti-PD-1 / 4-1BBL approach, which resulted with optimal antitumor efficacy without liver toxicity. To further optimize and develop this approach toward clinical program, the present inventors determined the optimal characteristics of the PD-1 mAb in the chimera. To determine whether PD-1 blockage is required for PD-1 / 4-1BBL activity, a non-blocking PD-1 antibody (clone RMP1-30) was generated with the 4-1BBL V152L mutation (Figure 5K) and compared it to the previously tested PD- 1 blocking version RMP 1-14 / 4- 1 BB L V 152L. RMP 1-14 / 4- 1BBLV152L had a superior anti-tumor activity than that of RMP1-30 / 4-1BBL V152L (Figures 5A and 5C) suggesting that PD-1 blockage adding potency for the PD-1 4-1BBL approach. ALT levels were associated with the doses and levels of anti-tumor efficacy, as previously reported (Figure 5B).

[0329] Given that PD-1 blockade was shown to be required for optimal anti-tumor activity and that RMP1-30 / 4-1BBL V152L provided a safe toxicity profile in anti-tumor effective doses, the PD-1 blockade monoclonal antibody RMP1-14 (Fc silent IgG; N297A), was combined with thenon-blocking PD-1 / 4-1BBL (RMP1-30 / 4-1BBL V152L) treatment to test if this can further improve the therapeutic window. Strikingly, the combination treatment exhibited potent antitumor activity with no liver toxicity compared to mono-therapy treatments (Figure 5D, 5E and 5F) Moreover, the mice that got complete response (tumor rejection) by the combination therapy were re-challenged with tumors which they then all rejected, suggesting the treatment provides long-lasting immune memory (Figure 5G). This synergistic effect supports the potential use of the aPD-1 / 4-1BBL chimera in a combination therapy with ICB (e.g., Keytruda) in addition to its single agent potent activity.

[0330] To evaluate the generality of this approach to additional tumor models, the present inventors tested PD-1 / 4-1BBL chimeras as monotherapy and in combination with aPD-1 in the MCA205 fibre sarcoma tumor model. Similar to the observation for the MC38 model, RMP1-30 / 4-1BBL-V152L + aPD-1 combination therapy resulted with potent efficacy and safety profile, superior to the cognate single agent treatments (Figures 5H and 51).

[0331] Next, the above findings were evaluated in the h4-lBB hPD-1 mouse model using human 4- IBB and human PD-1 molecules. The initial objective was to confirm the synergistic effect between human PD-1 antibody and human 4- IBB antibody in this mouse strain. To this end, the anti-tumor efficacy and toxicity of Keytruda (anti-human PD-1), Urelumab (anti-human 4-1BB), and their combination was assessed in the MC-38 tumor model. In this experimental setting, both Keytruda and Urelumab showed near-maximal anti-tumor activity as monotherapies, leading to no observable improvement with the combination treatment. (Figure 6A) In order to confirm the synergy between Keytruda and Urelumab, more aggressive tumor models should be analyzed. Importantly, at the tested concentrations, no liver toxicity was observed with Urelumab alone or in combination with Keytruda (Figure 6B). A fully human PD-1 / 4-1BBL molecule was developed incorporating the selected attenuation mutation, V 152L, (Figs. 6J, 6K, 6L and 6M) resulting in the Keytruda / 4-lBBL V152L construct. This engineered molecule demonstrated potent anti-tumor activity while maintaining a favorable safety profile, showing no evidence of liver toxicity in the h4-lBB hPD-1 mouse strain (Figure 6D, 6E and 6F).

[0332] The non-blocking hPD-l / 4-lBBL V152L construct (2H7 / 41BBL V152L) (Fig. 6N, 60, 6P and 6Q) was tested in combination with PD-1 blockade, as previously performed in the h4-lBB mPD-1 mouse model. Its anti-tumor activity and toxicity were evaluated in MC-38 tumor-bearing mice across a range of doses. Results indicated a dose dependent increase in anti-tumor potency, while toxicity remained unchanged at higher doses (Figure 6G and 6H).

[0333] The combination therapy was also tested using the aggressive B16F10 tumor model in our triple-humanized mouse model, which includes h4-lBB, hPD-1, and hPD-Ll. This time, the non-blocking PD-1 / 4-1BBL + PDL-1 treatment was combined to prevent competition between PD-1 molecules and further enhance treatment outcomes. In these settings, the combination therapy comprising 2H7-4-1BBL V152L + Avelumab N297A proved to be a potent treatment, given the aggressive melanoma model, with no signs of liver toxicity (Figures 7A-D).

[0334] To further confirm the synergistic effect of the combination treatment non-blocking PD-1 / 4-1BBL + PDL-1, it was tested once more using a different PDL-1 clone namely Atezolizumab. Once more, the potency of 2H7-4-1BBL + PDL-1 treatment in aggressive melanoma model was confirmed with no signs of ALT elevation (Figures 8A-D).

[0335] EXAMPLE 5

[0336] Discovery of Low Potency Urelumab Agonist Variants

[0337] Urelumab was engineered to significantly reduce its agonist potency. To achieve this, 15 receptor contact residues were identified within the CDRs of Urelumab from the co-crystal structure of Urelumab complexed with the 4- IBB receptor (Chin SM, Kimberlin CR, Roe-Zurz Z, Zhang, P et al., Structure of the 4-1BB / 4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nature Communications. 2018 Nov 8; 9(1): 4679). Specific amino-acid substitutions were introduced into all 15 receptor contact residues within the Urelumab heavy chain and light chain CDRs to generate 84 novel bivalent, mono- specific antibody variants. The effect of these substitutions were evaluated on cellular potency as measured by a commercial HEK human 4- IBB reporter cell line (BPS Biosciences). The nomenclature adopted for the Urelumab heavy chain CDR3 residues is shown in Table 1 herein below.

[0338] Table 1

[0339]

[0340] Table 2 and Table 3 mutations are based on Urelumab IgG4 (P229S) sequences as set forth in SEQ ID NOs: 51 and 52.

[0341] Initially, the cellular potency of these 84 novel bivalent, mono-specific Urelumab human IgG4 variants was determined in triplicate at a single lOnM concentration using a HEK human 4-1BB responsive reporter cells. 36 primary hits were identified with preliminary evidence of greater than 20% potency reduction relative to the parental Urelumab human IgG4 antibody agonist. These 36 primary hits were further characterized in a similar three-point (0.2nM; lOnM; 500nM)

[0342] secondary potency screen, from which 14 variants were selected for full 8-point dose response testing and EC50 determination, the results of which are presented in Table 2 below.

[0343] Table 2: Agonist Potency of Novel Bivalent, Monospecific Urelumab Human IgG4 Antibody

[0344] Variants

[0345]

[0346] *Estimated EC 50 as unable to generate full dose response curve up to highest concentration tested **Umab 1 is a bivalent Urelumab human IgGl LAGA positive control agent

[0347] EXAMPLE 6

[0348] Flow Binding Potency of Novel Bivalent, Monospecific Urelumab Human IgG4 Antibody Variants

[0349] To determine any correlation between agonist potency and 4- IBB target binding, we measured molecule flow binding potency to 4- IBB HEK NFkB reporter cells (BPS Biosciences), where each of 14 preferred bivalent, monospecific Urelumab agonist variants were tested in duplicate across a 5-fold concentration range from 6pM up to 500nM. The results of this flow binding screen are presented in Table 3 below. For 3 variants, including Umab38, Umab41 and Umab42, no significant change in binding potency despite 6-24-fold reductions in agonist potency was observed, suggesting for these 3 variants, there was no direct relationship between binding potency and agonism. For the remaining preferred 11 variants tested (including Umab 7, Umab 37, Umab45, Umab 47, Umab 57, Umab 59, Umab 68, Umab 74, Umab 77, Umab 78 and Umab 84), 91-fold to 2,300-fold reductions in target binding potency that were associated with reduced agonist potency was observed, suggesting for these variants, there was a direct correlation between agonist and binding potency.

[0350] Table 3: Flow Binding Potency of Novel Bivalent, Monospecific Urelumab Human IgG4

[0351] Antibody Variants to 4-1BB HEK NFkB Reporter Cells (BPS Biosciences)

[0352]

[0353] *Less than 2-fold reduction in target binding potency

[0354] EXAMPLE 7

[0355] Bi-specific Antibody Agonist Variant Characterization

[0356] 7 bi-specific antibody agonist variants that were targeted to a cell surface antigen expressed on 4- IBB responsive reporter cells were generated to determine whether antibody targeting could rescue the potency of highly attenuated Urelumab variants. These bi-specific molecules were created using a human IgGl LAGA backbone. Human HLA Class 1 antigen was selected as a universal cell surface antigen and used a corresponding anti-human HLA Class 1 binding antibody clone 2D7 as a specific targeting antibody for these studies. As depicted in Figure 9, four molecules per Urelumab bi-specific antibody agonist variant were generated, each based on the monovalent CH1-CL domain swapping bi-specific structure in which the agonist arm was incorporated withor without the CH / Cκ light chain arm exchange and combined with either a cell surface targeting arm (anti-HLA) or a non-cell surface targeting control antibody arm (anti-DNAse I).

[0357] For these CH1-CL domain swapping bi-specific antibody agonists, cellular potency was measured using a commercial 4- IBB reporter assay from Promega. The activity of various bi-specific anti-HLA Class I / Urelumab and anti-DNAse I / Urelumab variants is described in Table 4, herein below.

[0358] Table 4: Agonist Potency of Novel Monovalent, Bi-specific Urelumab Variant Antibodies

[0359]

[0360]

[0361]

[0362] Constructs generated are denoted Umab A, B, C or D to depict all four distinct bi-specific structures.

[0363] As seen in Table 4 and Figure 10, three preferred Urelumab variants displayed substantially higher maximal reporter activity relative to the parental bivalent Urelumab positive control agent (Umab 1). These variants included Umab 37 (Heavy chain G100A), Umab 45 (Heavy chain Y104G) and Umab 57 (Light chain Y32A), where the agonist arm was located in trans and on the opposite arm to the presence of the CH / Cκ light chain arm exchange. For constructs where the light chain arm exchange resided in cis on the same arm as the agonist variant, agonist activity was significantly reduced, suggesting that Urelumab agonism is sensitive to light chain modification and this bi-specific structure should be avoided if the therapeutic goal is to deliver high levels of 4- IBB agonism to tumor specific T cells.

[0364] EXAMPLE 7

[0365] Urelumab / PD-1 Bi-specific Agonist Characterization

[0366] aPD-l / a4-lBB bi-specific knob-into-hole (CH1-CL domain swapping)antibodies based on Umabl were developed - Umab37 (G100A), Umab47 (W106Y), Keytruda (anti PD-1 blocking antibody) and 2H7 (anti PD-1 non-blocking antibody) and built on human IgGl LAGA backbone. They were expressed and purified using Protein A followed by Cation Exchange and buffer exchange. The structure of each of these antibodies is illustrated in Figures 10A-H.

[0367] Activity assays were performed on HEK cells transfected with human 4- IBB cell-based reporter assay (HEK 4- IBB, Catalogue Code #79289, BPS Biosciences) and this cell line was transfected with human PD-1 to create double transfected 4-1BB / PD-1 for targeted activity assays.

[0368] Table 5: bi-specific antibody composition

[0369]

[0370]

[0371] Table 6: bi-specific antibody purity and activity

[0372]

[0373]

[0374] As seen in Table 6, the mutated Umab bi-specific variants exhibit reduced activity compared to Urelumab, with the attenuation already evident in the Umab WT bi-specific, which shows a 21- to 44-fold decrease in activity. Both Umab37 and Umab47 display significant attenuation when targeting 4- IBB reporter cells lacking PD-1. However, this attenuation is markedly reversed when assessing the constructs' activity on reporter cells co-expressing 4- IBB and PD-1. Based on the EC50 parameter, Umab47 is more attenuated than Umab37.

[0375] It is clear from the activity assay with 4- IBB / PD-1 Tx reporter cells that the blocking of PD-1 by Keytruda bi-specifics has synergy effect with 4- IBB activation since the luminescence level is elevated 3-10 fold compared to the non- blocking of PD-1 by 2H7 bi-specific counterparts.

[0376] In the activity assay with 4- IBB reporter cells (off-target activity), it was observed that the EC50 for Umab47 is challenging to determine, as its luminescence does not reach a plateau even at the highest antibody concentration tested. Conversely, Umab37 achieves a plateau at a lower concentration level with low luminescence level. This suggests that non-targeted activity may occur with Umab47 at high concentrations, whereas Umab37 may exhibit non-targeted activity at lower concentrations but with reduced potency.

[0377] EXAMPLE 8

[0378] Urelumab Heavy Chain Germline Reversion

[0379] In addition to receptor contact residues, 3 framework residues (positions 40, 42 and 64) were identified in the Urelumab heavy chain that deviated from the VH4-34 germline sequence. In contrast, the Urelumab light chain encoded a fully germline VK3-11 sequence that lacked any predicted N-linked glycosylation sites.

[0380] To further reduce the potential immunogenicity risk of a future therapeutic agent, 4 heavy chain germline reversion variants (3 single substitutions and one compound triple substitution variant) were generated and the effect of these reversions on cellular potency was determined as measured by a HEK human 4- IBB reporter cell line (BPS Biosciences). It was found that a variant heavy chain with reversion of all three residues to germline sequence (S40P, E42G, E64K) did notresult in any loss of cellular potency, suggesting this heavy chain variant could be incorporated into any future therapeutic lead candidate to further mitigate immunogenicity risk.

[0381] Table 7: Effect of Heavy Chain Germline Reversion on In Vitro 4-1BB Cellular Potency

[0382]

[0383] Overall, these observations provide critical in vitro proof of concept that the activity of the newly discovered low potency antibody agonist variants described herein have the potential to be fully rescued when delivered via the appropriate antibody targeting to a therapeutically relevant immune cell and as such, have great potential to dramatically improve the therapeutic index of 4- IBB agonists for the treatment of various human cancers responsive to T cell-based immunotherapies.

[0384] Table 8: Summary of sequences

[0385]

[0386]

[0387]

[0388] • Additional sequences are provided in Table 5

[0389] Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

[0390] It is the intent of the applicant(s) that all publications, patents and patent applications referred to in this specification are to be incorporated in their entirety by reference into the specification, as if each individual publication, patent or patent application was specifically and individually noted when referenced that it is to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting. In addition, any priority document(s) of this application is / are hereby incorporated herein by reference in its / their entirety.

Claims

WHAT IS CLAIMED IS:

1. An isolated polypeptide comprising at least one monomer of a 4- IBB ligand (4-1BBL) having at least one mutation which reduces 4- IBB signaling, when comprised in a homotrimer, by at least 100 fold and no more than 10,000 fold, as compared to a wild-type homotrimer of 4-1BBL, wherein the polypeptide has an anti-tumor activity, wherein the polypeptide binds specifically to 4- IBB.

2. The isolated polypeptide of claim 1, wherein said at least one mutation reduces induction of NFKB.

3. The polypeptide of claims 1 or 2, being a single-chain homotrimer.

4. The polypeptide of any one of claims 1-3, wherein said at least one monomer has a mutation at position 100, 115 and / or 152, wherein coordinates of said position are according to SEQ ID NO: 1.

5. The polypeptide of claim 4, wherein said at least one monomer comprises at least one of the following mutations: V152L, V100K, V152K, L115D or V100H.

6. The polypeptide of claim 4, wherein said at least one monomer comprises a V152L mutation.

7. The polypeptide of any one of claims 1-6, wherein said at least one monomer comprises an amino acid sequence at least 90 % identical to SEQ ID NO: 2.

8. The polypeptide of any one of claims 1-7, wherein said at least one monomer comprises the amino acid sequence as set forth in SEQ ID NOs: 5-8.

9. The polypeptide of any one of claims 1-7, wherein said at least one monomer comprises three monomers and comprises the amino acid sequence as set forth in SEQ ID NOs: 21-24.

10. The polypeptide of any one of claims 1-7, being attached to an antibody having an Fc region, wherein said antibody targets a protein on intratumor T cells.

11. The polypeptide of claim 10, wherein said protein is an immune checkpoint protein.

12. The polypeptide of claims 10 or 11, wherein the polypeptide is covalently attached to the antibody.

13. The polypeptide of claim 12, wherein the polypeptide is covalently attached to the antibody via a linker.

14. The polypeptide of claim 13, wherein said linker comprises an amino acid sequence as set forth in SEQ ID NO: 4.

15. The polypeptide of claim 10, wherein said polypeptide is attached to said Fc region.

16. The polypeptide of claims 10 or 15, wherein said Fc region comprises a mutation which reduces binding to an Fc receptor.

17. The polypeptide of claims 10 or 15, wherein said Fc region is Fc receptor silent.

18. The polypeptide of claim 16, wherein said mutation is a LALA mutation.

19. The polypeptide of any one of claims 11-18, wherein said immune checkpoint protein is selected from the group consisting of PD-1, PDCTLA-4, TIGIT, LAG-3, TIM-3, ICOS, BTLA, 4-1BB, GITR and OX-40.

20. The polypeptide of claim 19, wherein said immune checkpoint protein is PD-1.

21. The polypeptide of claim 20, wherein said antibody is a PD-1 blocking antibody.

22. The polypeptide of claim 20, wherein said antibody is a PD-1 non-blocking antibody.

23. The polypeptide of claim 21, comprising complementary determining regions (CDRs) as set forth in SEQ ID NOs: 9-11 in a heavy chain with an N to C orientation and CDRs as set forth in SEQ ID NOs: 12-14 in a light chain with an N to C orientation.

24. The polypeptide of claim 22, comprising CDRs as set forth in SEQ ID NOs: 15-17 in a heavy chain with an N to C orientation and CDRs as set forth in SEQ ID NOs: 18-20 in a light chain with an N to C orientation.

25. An article of manufacture comprising the polypeptide of claims 1 or 22 and a PD-1 blocking antibody and / or a PDL-1 antibody.

26. A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the polypeptide of any one of claims 1-24, thereby treating the cancer.

27. The polypeptide of any one of claims 1-24 for use in treating cancer.

28. The article of manufacture of claim 25, for use in treating cancer.

29. The method or polypeptide for use of any one of claims 26-27, further comprising administering to the subject a second agent simultaneously or sequentially with the polypeptide, wherein the second agent is a PD-1 blocking antibody and / or a PDL-1 antibody.

30. The method, polypeptide or article of manufacture of any one of claims 26-29, wherein the cancer is selected from the group consisting of: bladder cancer, breast cancer, uterine / cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, kidney cancer, head and neck cancer, lung cancer, stomach cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, neoplasm of the central nervous system, lymphoma, leukemia, myeloma, sarcoma, and virus-related cancer.

31. A pharmaceutical composition comprising the polypeptide of any one of claims 1-24.

32. The pharmaceutical composition of claim 31, wherein the polypeptide is the polypeptide of claim 1 or 22.

33. The pharmaceutical composition of claim 32, further comprising a PD-1 blocking antibody and / or a PDL-1 antibody.

34. A nucleic acid encoding the polypeptide of any one of claims 1-24.

35. An expression vector comprising the nucleic acid of claim 34.

36. A cell transformed with the expression vector of claim 35.

37. A method of producing a polypeptide comprising:(a) culturing the cell of claim 36 under conditions which allow the expression of the polypeptide; and(b) isolating the polypeptide from the cell.

38. A 4-1BB agonistic antibody which binds specifically to 4-1BB and comprises CDRs of Urelumab, wherein at least one of said CDRs comprises at least one amino acid substitution which reduces 4-1BB signaling by at least 50 fold and no more than 10,000 fold, wherein the molecule has an anti-tumor activity.

39. The 4-1BB agonistic antibody of claim 38, wherein said at least one mutation is in a heavy chain of said antibody.

40. The 4-1BB agonistic antibody of claim 39, wherein said at least one mutation is selected from the group consisting of W34A, G100A, Y104G and W106Y, wherein the numbering is according to the wild type sequence as set forth in SEQ ID NO: 51.

41. The 4-1BB agonistic antibody of claim 39, wherein said at least one mutation is in a light chain of said antibody.

42. The 4-1BB agonistic antibody of claim 39, wherein said at least one mutation is selected from the group consisting of Y32A, Y32N, Q89G, N93G, W94G, P95G and L98G, wherein the numbering is according to the wild type sequence as set forth in SEQ ID NO: 52.

43. A bispecific antibody comprising:(i) a first antigen binding moiety which specifically binds to 4-1BB and comprises CDRs of Urelumab, wherein at least one of said CDRs comprises at least one amino acid substitution which reduces 4-1BB signaling by at least 50 fold and no more than 10,000 fold; and(ii) a second antigen binding moiety which specifically binds to a protein on intratumor T cells,the bispecific antibody having anti-tumor activity.

44. The bispecific antibody of claim 43, wherein said protein is an immune checkpoint protein.

45. The bispecific antibody of any one of claims 43-44, wherein said immune checkpoint protein is selected from the group consisting of PD-1, PDCTLA-4, TIGIT, LAG-3, TIM-3, ICOS, BTLA, 4-1BB, GITR and OX-40.

46. The bispecific antibody of claim 45, wherein said immune checkpoint protein is PD-1.

47. The bispecific antibody of claim 46, wherein said antibody is a PD-1 blocking antibody.

48. The bispecific antibody of claim 46, wherein said antibody is a PD-1 non-blocking antibody.

49. A pharmaceutical composition comprising the antibody of any one of claims 43-48.

50. The pharmaceutical composition of claim 49 further comprising a PD-1 blocking antibody and / or a PDL-1 blocking antibody.

51. An article of manufacture comprising the antibody of any one of claims 43-48 and an additional PD-1-blocking antibody or PDL-1 blocking antibody.

52. A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the bispecific antibody of any one of claims 43-48, thereby treating the cancer.

53. The method of claim 52, further comprising administering to the subject a second agent simultaneously or sequentially with the polypeptide, wherein the second agent is a PD-1 blocking antibody and / or a PDL-1 antibody.

54. The method of claims 52 or 53, wherein the cancer is selected from the group consisting of: bladder cancer, breast cancer, uterine / cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, kidney cancer, head and neck cancer, lung cancer, stomach cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, neoplasm of the central nervous system, lymphoma, leukemia, myeloma, sarcoma, and virus-related cancer.